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ABSTRACT 
CONJUGATED POLYMER NANOPARTICLES FOR BIOMEDICAL 
APPLICATIONS INCLUDING BIOIMAGING AND DRUG DELIVERY 
Özlem Ünal 
M.S. in Department of Chemistry 
Supervisor: Assoc. Prof. Dr. Dönüş TUNCEL 
July, 2013 
In this study, the ability of fluorene-based conjugated polymer nanoparticles in the 
delivery of anticancer therapeutics and bioimaging was investigated through in vitro 
cytotoxicity assessments and fluorescence imaging. In order to prepare the 
nanoparticles, green light emitting polymer,poly[(9,9-bis{6-
dimethylaminohexyl}fluorenyl-2,7-diyl)-co-(1,4-benzo-{2,1,3}-thiodiazole)] 
(PDAFBT),was synthesized via Suzuki coupling reaction and characterized by 
nuclear magnetic resonance (NMR), electrospray ionization mass spectroscopy (ESI-
MS), matrix assisted laser desorption ionization mass spectroscopy (MALDI), fourier 
transform infrared spectroscopy (FT-IR), UV-visible absorption spectroscopy (UV-
Vis) and fluorescence spectroscopies. PDAFBT nanoparticles were synthesized 
through reprecipitation method which is based on the injection of the polymer 
solution in a good solvent into a poor solvent for the polymer to enhance the collapse 
of polymer chains in the form of spherical nanoparticles. Anti-cancer drug, 
camptothecin (CPT), was entrapped into the PDAFBT nanoparticles via hydrophobic 
interaction during the nanoparticle formation. Size, surface charge, morphology and 
optical characterizations of blank and CPT loaded nanoparticles were investigated by 
dynamic light scattering (DLS), scanning electron microscopy (SEM), transmission 
electron microscopy (TEM), UV-Vis and fluorescence spectrocopies. In order to 
investigate the properties of nanoparticles as drug carrier, drug encapsulation 
efficiency (EE) and drug loading efficiency (LE) were determined and EE was found 
to be as 92% and 75% for the 1:35 and 1:25 polymer to drug ratios, respectively, 
while LE of PDAFBT nanoparticles was determined as 2.67±0.3 %. Preliminary 
drug release profile which needs to be strengthen statistically, of PDAFBT 
nanoparticles was analyzed and showed that almost 100% of the loaded CPT was 
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released steadily during first 48h time period indicating that the release of CPT is not 
a burst process. Stability of blank and CPT loaded PDAFBT nanoparticles was 
examined in different biological media including cell culture medium, bovine serum 
albumine (BSA) andhuman serum. The precipitation in nanoparticle dispersion was 
observed due to adsorption of proteins onto the surface of polymers. 
In vitro dose dependent cytotoxicity of blank and CPT loaded PDAFBT 
nanoparticles was assessed through 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazoliumbromide (MTT) toxicology assay on human carcinoma breast cancer cell 
lines, namely,MDA-MB-231, MDA-MB-157 and MCF-7 cells. The blank PDAFBT 
nanoparticlesdo not exhibit significant toxicity to MDA-MB-231 and MDA-MB-157 
cells up to 40 μM, however, a linear decrease on the viability of MCF-7 cells was 
detected ata concentration higher than 2.5 μM and nearly 40% of the cells were dead 
at 40 μM.The half maximal inhibitory concentration (IC50 ) values of free CPT and 
CPT loaded PDAFBT NPs were calculated to be 4.50μM and 1.35μM for MDA-MB-
157 cell line, respectively, and 1.97μM and 1.05μM for MDA-MB-231 cells, 
respectively. These results indicate clearly that the CT-loaded nanoparticles are more 
efficient than free CPT in destroying the cancer cells. Fluorescent microscope images 
show also the efficient internalization of blank and CPT-loaded nanoparticles by 
MDA-MB-157 and MDA-MB-213 cell lines. Preliminarily in vivo studies have been 
performed on embryonic zebra fish and C. Elegans animal models using these 
nanoparticles and the efficient uptake of nanoparticles by the tissues have been 
observed by fluorescent microscopy. This results indicate that CPNs are promising 
for imaging and delivery vehicles for time and dose dependent treatments. 
Keywords: Conjugated polymer nanoparticles, drug delivery, bioimaging. 
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ÖZET 
KONJUGE POLİMER NANOPARÇACIKLARIN İLAÇ TAŞINIMI VE 
BİYOLOJİK GÖRÜNTÜLEME İÇEREN BİYOMEDİKAL 
UYGULAMALARI 
Özlem Ünal 
   Kimya Bölümü Yüksek Lisans Tezi  
Tez Yöneticisi : Doç. Dr. Dönüş TUNCEL 
Temmuz, 2013 
Bu çalışmada, floren tabanlı konjuge polimer nanoparçacıkların antikanser terapatik 
taşınımı ve biolojik görüntüleme verimi, canlı dışı toksik inceleme ve floresan 
görüntüleme yöntemleriyle incelenmiştir. Nanoparçacıkların hazırlanmasında yeşil 
ışıyan poli[(9,9-bis{6-dimetilaminohekzil}florenil-2,7-dil)-ko-(1,4-benzo-{2,1,3}-
tiyadiazol)](PDAFBT)  polimeri kullanılmıştır. PDAFBT polimeri, Suzuki kenetleme 
reaksiyonu ile sentezlenmiş, karekterizasyonu nükleer manyetik rezonans 
spektroskopileri ( H1-NMR, C13-NMR), elektrosprey ionizasyon kütle spektroskopisi 
(ESI-MS), matris destekli lazer salınımlı kütle spektroskopisi (MALDI), fourier 
transformu kızılötesi spektroskopisi (FT-IR), UV-Vis absorbans ve floresans 
spektroskopileri ile yapılmışmıştır. PDAFBT nanoparçacıkları, çözücünün 
hidrofilikliğinin azaltılmasına dayanan  ve polimer zincirlerinin çökerek küresel 
forma dönüşmesine dayanan geriçöktürme yöntemi ile hazırlanmıştır. Anti-kanser 
terapatiği olarak kullanılan kamptotesin, PDAFBT nanoparçacıklarının içerisine 
nanoparçacık oluşumu sırasında etkin olan hydrofobik etkileşimle yüklenmiştir. 
Nanoparçacıkların boyut, yüzey yükü, şekilsel ve ışıksal karekterizasyonları dinamik 
ışık saçılımı (DLS), geçirimli elektron (TEM), taramalı elektron mikroskopileri 
(SEM), UV-Vis absorbans ve fluoresans spektroskopileri ile yapılmıştır. 
Nanoparçacıkların ilaç taşıyıcı olarak özelliklerinin incelenmesi amacıyla, ilaç 
kapsülleme (EE) ve ilaç taşıma (LE) verimleri analiz edilmiş ve ilaç kapsülleme 
verimi 1:35 ilaç-polimer oranında % 92, 1:25 ilaç-polimer oranında % 75 olarak 
bulunurken, ilaç taşıma verimi ise % 2.67±0.3 olarak belirlenmiştir. Öncül bir 
çalışma olan ve sonuçları istatiksel olarak güçlendirilecek PDAFBT 
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nanoparçacıkların ilaç salınım profili analiz edilmiş ve ilaç miktarının yaklaşık % 
100 ünün 48 saat içinde salındığı gözlenmiştir. 
Boş ve kamptotesin yüklü PDAFBT nanoparçacıkların hücre kültürü ortamı, bovin 
serum albumin (BSA) ve insan serumu içeren farklı biyolojik ortamlardaki stabilitesi 
test edilmiş, insan serumu ve bovin serum albumin ortamında proteinlerin polimer 
yüzeyine tutunması nedeniyle nanoparçacık solusyonunda çökme gözlenmiştir.  
Boş ve ilaç yüklü nanoparçacıkların canlı dışı (in vitro) doza bağlı toksik 
incelenmesi, tetraazolyum boyasının redüklenmesine dayanan MDA-MB-231, 
MDA-MB-157, MCF-7 insan göğüs kanseri hücre hatları üzerinde MTT toksikoloji 
testi ile yapılmıştır. Sadece kamptotesin ve kamptotesin yüklü PDAFBT 
nanoparçacıklar için  % 50 inhibe edici konsantrasyon (IC50) değerleri MDA-MB-
157 hücreleri için 4.50 μM ,1.35 μM  ve MDA-MB-231 hücleri için 1.97μM ve 
1.05μM’dır ve polimer kapsuller sayesinde ilacın hücrerele etkin alınımı gösterir. 
PDAFBT ve PPFBT nanoparçacıkların yaşayan canlı modelleri olan zebra balığı ve 
C. Elgans üzerindeki yapılan görüntülemeleri nanoparçacıkların dokulara etkin bir 
şekilde nüfuz ettiğini desteklemektedir ayrıca zamana ve doze bağlı uygulamalar için 
umut vericidir. 
Anahtar Kelimeler: Konjuge polimer nanoparçacıklar, ilaç taşıma, biyolojik 
görüntüleme 
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CHAPTER 1 
1. INTRODUCTION 
 
Recent developments in nanotechnology provide special biomedical tools which are 
capable to deliver pharmaceuticals and biological agents with high efficiency, in a 
controlled time-scale and a safe way.These nano devices have an importance for drug 
delivery, molecular imaging and biomarkers. Traditional therapeutic approaches 
provide only non-specific drug mixtures but an efficient delivery needs more 
attention to design smart systems through a multifunctional aspect which target to 
visualize the carriers with an effective screening and increase the bio-compatibility. 
Nanoparticles improve the bio-availability of water-insoluble drugs, protect the drugs 
from physiological barriers and increase the body tolerability to the drugs and 
thereby, enhance the efficiency of drug delivery. Tracking the bio-distribution of 
nanocarriers is crucial to investigate the interaction of therapeutics with the sections 
of tissues and cells. Among a number of screening methods, fluorescence imaging 
has important impact to control the bio-distributions of pharmaceutical carriers in 
drug delivery research.  
Typical fluorescent imaging agents containing conventional dyes have 
photobleaching and toxicity problems. Although quantum dots have high brightness 
and photostability, they are cytotoxic due to heavy metals from their nanocrystal core 
and their bio-compatibility is not high enough for biological applications.These 
limitations urgethe design of new fluorescent materials in drug delivery research. 
Development of fluorescent conjugated polymer materials is very promising in 
imaging guided drug delivery applications due their high brightness, good 
photostability and lower toxicity. Fluorene based conjugated polymer nanoparticles 
which are prepared through miniemulsion57 or reprecipitation59 methods have wide 
range of applications from nanomedicine 70,78,79 to molecular electronics.63-64 
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CHAPTER 2 
2. BACKROUND 
 
2.1. Conjugated Polymers 
 
Broad range of polymers exhibit insulating properties, however if polymers are 
designed in such a way that having conjugated backbone, they could conduct the 
electricity (Figure 1). These polymers are called conjugated polymers and consist of 
unsaturated sp2 or sp hybridized carbon atom chains including pz orbitals which 
forms π overlap with adjacent unsaturated carbon atom and these overlaps form 
delocalization of π electrons along the polymer chain.1-2 
 
 
Figure 2. 1. Conjugated and isolated π bonds in 1,3,6heptene.. 
 
This πstateformation leads to a frontier electronic gap, named as π-band gap which is 
relatively smaller than σ-band gap and varies from 1.5 eV to 4 eV depending on the 
structure.The energy spacing between highest occupied molecular orbital (HOMO) 
and lowest unoccupied molecular orbital (LUMO) is defined as band gap energy and 
identifies the level of conductivity (Figure 2). The ability of semiconducting 
behaviours of conjugated polymers come from this low energy band gap between 
conduction band (HOMO) and valence band (LUMO).1-4 Density of charge carriers 
affects the conductivity. Small band gaps in conjugated polymers provide ease in 
doping,which corresponds to partial oxidation or reduction, and charge carrier 
generation.4-6 
The first conducting polymer was poly(acetylene) and synthesized using Ziegler-
Natta catalyst in 1958 by K. Ziegler , G. Natta who were awarded 1966 Nobel Prize 
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in Chemistry.7 However only conjugation is not enough for being conductive, thus 
charge carriers which contains holes (missing electrons or positive charge) or 
electrons, have to be added to system (doping) to allow charge to migrate along the 
long distance. In 1974, Shirakawa and coworkers discovered that treatment with 
halogen vapour increases the conductivity of polyacetylene 109 times more than its 
natural form and were awarded the Nobel Prize 2000 “for the discovery and 
development of electrically conductive polymers” 8-9 
 
 
Figure 2.2. General band picture of an insulator, a semiconductor,a metal and 
conductivity of conjugated polymers compared to those of materials. 
Conjugated polymers could also exhibit photoluminescence (PL) properties when 
they are excited with a suitable wavelength of a light. Luminescence is the 
spontaneous emission of light from electronically excited states in the substances 
under optical excitation and it can be named as fluorescence when light emits from 
singlet excited states and phosphorescence when light emits from triplet excited 
states.10 Jablonski Diagrams are used to explain light absorption and emission 
phenomena through illustrating electronic ground and excited states with a number of 
vibrational energy levels (Figure 3). When a photon at particular energy is absorbed 
by the fluorophore (fluorescent molecule) which is excited to higher vibrational 
levels of S1 or S2,several pathways can be followed including vibrational relaxation, 
internal conversion, fluorescence, intersystem crossing, and phosphorescence to 
dissipate the energy. Conjugated polymers exhibit allowed absorptions and emissions 
and generally luminescence efficiency changes with the delocalization and 
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polarization of the electronic structure. For example, highly delocalized and 
polarizable polymers are weakly luminescent due to dissociation of photo-generated 
electron-hole pairs through the chain  in order to generate charge carriers, then 
combination of these free carriers to form triplet or deactivation by non-radiative 
relaxations occur.11 
 
 
Figure 2.3. Ilustration of radiative and nonradiative transitions between the 
electronic states in a molecule after absorption of a photon by Jablonski diagram.12 
Electroluminescence, emitting light due to excitation by the flow of electric current, 
became another important feature of conjugated polymers with the discovery of 
electroluminescent property of semiconductive conjugated polymer poly(p-
phenylenevinylene) by Friend et al in 1990.13 In the last decade, polymer light 
emitting diodes (PLEDs)  (Figure 4a), which produce light by the fast decay of 
excited molecular states in the polymers, have been under great interest and 
polythiophenes14, polyphenylenes15, polyfluorenes16 were used for various 
electroluminescent applications due to their comparable efficiency and brightness to 
their inorganic analogs.17 In the area of photovoltaics which is based on producing 
electrolytic cells to generate electrical current when exposed to light18 (Figure 4b), 
conjugated polymers are widely preferred semiconductors due to their ability of 
absorbing significant fraction of sun light and ease of processing on flexible films at 
low cost.19 With the discovery of bulk heterojunction, the improvements in 
conjugated polymer based photovoltaic cells (PV) through the attempts to achieve 
smaller band gaps, wider band widths,higher carrier mobilities have been obtained 
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and their power efficiency enhanced 100 folds  greater in the past decade.20 As 
another photonic application, conjugated polymers are unique class of solid state 
laser materials due to their emission spectrum which involves entire visible 
spectrum.21 
 
 
Figure 2.4. Schematic representation of a) photovoltaic cell b) light emitting diode 
based on conjugated polymer. 
Apart from being high performance plastic photonic devices, conjugated polymers 
are versatile chemosensors performing for variety of sensing methods such as 
conductrometric sensors due their conductivity, potentiometric sensors which is 
developed on the basis of their reversible nature of redox processes, calorimetric 
sensors based on the sensitivity of CP’s band gap with respect to polymer 
conformation22. Moreover, CPs are preferred significantly for the applications as 
fluorescent chemosensors to detect the substances from biomolecules to explosives23-
24 due to their direct fluorescent response to the analytes in the environment, 
conformational change of backbone by the interaction with analyte, ease of 
substitution of flexible backbones with receptor groups to achieve molecular 
recognition and amplify the fluorescence signals.25 Furthermore, conjugated 
polymers have applications also in the new emerging areas such as artificial muscles 
and nano-electromechanical systems.26-27 
2.1.1 Fluorene Based Conjugated Polymers  
Polyfluorenes (PFs) are stepladder types polyphenylenes, being very promising for 
the fabrication of  LED28-29and PV diodes30-31.  The most important advantage in the 
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area of optoelectronics of these polymers is their high photoluminescence efficiency 
both in solution and in solid films with the emission of blue light in the visible 
spectrum due to their rigid biphenyl units providing a large band gap for blue 
emission.32-33 They show better thermal- and photo-stability than their analogs in the 
optoelectronics.34 Moreover, highly reactive protons at C-9 position of the fluorene 
unit allow substitutions at this  position without destroying their electrochemical 
properties and provides the opportunities to improve the solubility and processability 
of these polymers.35-36 Various fluorene copolymers are synthesized, in order to 
obtain wide range of emission colors in the entire visible spectrum and tune their 
band gaps as shown in Figure 5.28 Apart from applications in optoelectronics, PFs are 
widely used in bioimaging37and chemosensory38applications. 
 
 
Figure2.5. Different emission colors based on backbone structure of co-
polyfluorenes. 
 
2.1.2. Synthesis methods of conjugated polymers 
Polymerization is the process of combination of desired monomers through stepwise 
oligomer formation to long chains or adding unsaturated monomers onto the active 
site of the growing polymers in a controlled manner.39 Synthetic methods are 
significant to obtain polymers including well defined molecular weight and 
polydispersity. Various methods have been developed to synthesize conjugated 
polymers and tried to design pure, soluble, efficient electrochemical features 
containing polymers by preserving delocalized pi states in the polymer chain. One of 
these methods is electrochemical polymerization which is based on deposition of 
polymer thin films from monomers such as aniline, pyrole, thiophene on the anode.40 
Experimentally, polymerization is carried outin a single compartment 
electrochemical cell with three electrodes configuration and electrochemical bath 
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consists of monomer and electrolyte in an appropriate solvent.41 When going into a 
literature research in this area, it can be seen that, the electrochemical synthesis of 
conducting polypyrole by Diaz et al. provided a new synthetic way in the polymer 
science and triggered various studies in the field.42 Polythiophene and 
poly(isothionaphthalene) have been other electrochemically prepared conductive 
polymers which is carried out Wuld et al.43 Electrochemical synthesis of 
polythiophenes in microemulsion medium by using cationic surfactant has been 
reported by Murugan and his co-worker.44 Electrochemical synthesis of these 
conductive polymers consists of especially polypyroles and polythiophenes provides 
many enhanced applications in the field of optoelectronics.41 Besides, catalytic chain 
polymerization, which is mainly used for the synthesis of polyvinylenes and 
polyphenylenevinylenes45, chemical oxidation polymerization for the preparation of 
polyacetylenes and polyanilines unfortunately with high amount of side products40, 
photochemical polymerization typically for the synthesis of polydiacetylenes46, are 
other feasible approaches for the synthesis of conjugated polymers. 
Transition metal mediated cross coupling reaction is one of the most powerful 
techniques to synthesize conjugated polymers via carbon-carbon bond formation 
between sp2-sp2 or sp2-sp hybridized carbon atoms and recently was awarded with 
the Nobel Prizes in Chemistry 2010 for palladium catalyzed cross couplings in 
organic synthesis.47 Nucleophilic substitutions at sp2 and sp carbons are not easy and 
need transition metal catalysts.The theory of cross coupling reactions is basically, 
assembling of carbon atoms of two reactants on the transition metal through the 
metal-carbon bonds and resulting carbon-carbon bonds between these couples after 
introducing them into very close proximity as shown schematically in Figure 6. 
Generally, palladium (or nickel) catalyst couplings are believed to follow the similar 
catalytic cycle with some changes in the steps including activation of the catalyst and 
release of the product.The reactions start with oxidative addition, reacting of Pd(0) 
catalyst with organohalide and changing to Pd(II) with the formation of 
organopalladium compound via C- Pd bonding, after that step there are some 
differences in different type of couplings but transmetallation is the common step 
consisting of the co-ordination of nucleophile (second carbon source) to Pd and 
assembling of two reagents on the Pd and followingly reacting of these couples with 
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each other. After carbon carbon bond formation is achieved then regeneration of  
Pd(0) and releasing of newly formed organic compound occur at the final step which 
is called as reductive elimination. 
 
         
Figure 2. 6. Basic representation of metal catalyzed C-C bond formation. 
 
Discoveries in cross coupling reactions are triggered by publications of Kumada et. 
alin the beginning of 1972, including carbon-carbon bond formation by cross 
coupling of Grignard reagents with organic halides through Ni catalyst.48 Again in 
1972, a new cross coupling reactions of aryl, vinyl halides and olefins in the presence 
of Pd catalyst has been reported by Heck et al.49 and it became the most important 
carbon-carbon bond forming reaction under the truth that palladium salts are mostly 
useful. In the case of Heck coupling, general catalytic cycle is followed between 
organohalide and olefin but differently carbon-carbon bond forms via migratory 
insertion including migration of carbon atom on Pd to one of the carbon atoms of the 
coordinated olefin and release of newly formed organic compound through β-H 
elimination (Figure 7). 
 
Figure 2. 7. Reaction Mechanism of Heck47 cross-coupling. 
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In 1979, another most attractive approach to carbon-carbon bond formation has been 
discovered by Suzuki and Miyaura including trans metal catalyzed cross coupling 
between an organoboron compound and organic halide.50 Differently from Heck 
coupling, reaction mechanism of Suzuki coupling involves the activation of 
organoboronic acid through a base and facilitation of transmetallation. Choosing the 
organoboronic compounds provides various advantages such as making coupling 
reactions more practical due to the weak nucleophilicity and stability of 
organoborones, having high chemoselectivity, providing to run the reaction at mild 
conditions and non-toxicity of boron compounds. Moreover, the most important 
benefit of this coupling is to tolerate many different functional groups and providing 
efficient couplings between biaryl, aryl-vinyl, alkyl-aryl and alkyl-alkyl 
compounds.47Due to these advantages, Suzuki cross-coupling reaction was preferred 
for the synthesis of polymers in this thesis. 
 
Figure 2. 8. Reaction Mechanism of Suzuki Cross Coupling51. (Reprinted with the 
permission from ref 51. Copyrigth (1995) American Chemical Society) 
 
In 1977, Negishi and coworkers reported using organozinc ligands as nucleophiles in 
the palladium catalyzed couplings containing organozinc and organoaliminum 
compounds.52 
One of the most versatile organometallic reagent in Pd catalyst cross coupling 
reactions is organotin which is used as a novel method for carbon-carbon bond 
generation between an organohalide and organostanne developing through Stille and 
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coworkers.53 The most important advantage of this reaction is to tolerate variety of 
functional groups containing alcohols, ketones, enones, esters, nitriles, nitro groups. 
In the reaction, Pd catalyst is coupled with an electrophile with a vinyl or a aryltin 
compound through oxidative addition. After transmetallation with organostanne, 
functional group of organostanne replaces the halide anion on Pd(II) complex and 
finally coupled product is released with the reductive elimination (Figure 8). 
Sonogashira54 reaction which is based on the reaction between aryl and alkynes under 
Pd and Cu catalysis, Yamamato55 obtaining biaryl from aryl halides in the presenceof 
Ni catalyst, are other coupling reactions to synthesize conjugated polymers. 
 
Figure 2. 9. Reaction Mechanism of Stille Cross Coupling.53 (Reprinted with the 
permission from ref 53. Copyrigth (1986) Wiley) 
 
2.2. Conjugated Polymer Nanoparticles  
Conjugated polymer nanoparticles (CPNs) can be termed as colloidal dispersions of 
lyophobic polymers surrounded by low molecular weight solvents. First colloidal 
dispersions of CPs have been reported in 1980’s from polyacetylene, polyaniline and 
polypyroles.56 In order to benefit conjugated polymers in biological applications, 
water soluble forms have to be prepared of these resulting polymers through 
substitutions with hydrophilic or ionic side chains. However this method can cause 
decrease in quantum yields or aggregations of the polymers in water. In order to 
11 
 
avoid these undesired situations, conjugated polymers can be converted into the 
water soluble nanoparticles through several physical steps. Conjugated polymer 
nanoparticles are highly versatile tools in wide range of applications from 
optoelectronics to biological fields due to their major advantages including 
mechanical and photostability, ease in surface functionalization and emissions in a 
wide range of wavelengths. 
2.2.1 Preparation Methods of Conjugated Polymer Nanoparticles 
CPNs could be prepared through miniemulsion or reprecipitation methods. Among 
them, miniemulsion method is based on generating emulsions from conjugated 
polymers dissolved in organic solvent.57 Figure 9 shows the preparation CPNs 
through miniemulsion method. High stability of aqueous dispersion of nanoparticles 
can be preserved through combined effects of surfactant and co-stabilizer molecules 
which builds osmatic pressure in the droplets. With this technique, submicron 
polymer nanoparticles (75-250 nm) can be obtained by adjusting amount of 
surfactants and the concentration of the polymer solution. Landfester and coworker 
reported stable miniemulsions from ultra-hydrophobe methyl substituted ladder type 
poly(para phenylene) by using sodium dodecyl sulfate as surfactant in the size range 
about 150 nm and also it was investigated that the size of nanoparticles can decrease 
to nearly 75 nm by increasing the surfactant.58 
 
Figure2.10. Miniemulsion method for the preparation of polymer nanoparticles.57 
(Reprinted with the permission from ref 57. Copyrigth (2009) Wiley) 
Another developed method to obtain conjugated polymer nanoparticles is 
reprecipitation.59 This method is based on hydrophobic effect through the decrease in 
the hydrophobicity of solvent. After dissolving polymer in a solvent such as 
tetrahydrofuran (THF) which dissolves polymer well, then the polymer solution is 
rapidly injected into to excess amount of water having poor solvent quality for the 
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polymer (Figure 10). Polymer chainstend to collapse down triggered by the decrease 
in contact area with solvated molecules due to decrease in solvent property.56,60 
Through this method, it is possible to prepare spherical nanoparticles in a wide range 
of sizes (3-150 nm) by adjusting the concentration, chemical structure and molecular 
weight of the polymer. There are many examples in the literature for the preparation 
of conjugated polymer nanoparticles based on reprecipitation method. One of them 
consist of polymer nanoparticles from poly(phenylene ethynylene) derivatives which 
are sensitive to labeled oligonucleotides and used to detect them by fluorescence 
quenching.61 Resulting polymer nanoparticles were prepared through injection of the 
polymer solution in dimethyl sulfoxide into the excess amount of SSED (saline, 
sodium phosphate, EDTA) buffer.  
 
Figure 2. 11. Reprecipitation method for the preparation of polymer nanoparticles. 
. 
2.2.2 Photophysical Properties and Optoelectronic Applications of CPNs 
Nanoscale organic electronics became more attractive with the development in 
nanoscience. The use ofconjugated polymer nanoparticles in organic devices have 
been demonstrated successfully in many studies. Applicability of these polymer 
nanospheres in organic electronics provides controlled multilayer deposition and 
high throughput capacity to the surface without consuming high amount of materials 
and most importantly environmental friendly processing.61-62 The fabrication process 
consists of printing of polymer dispersion to a non-emitting  matrix through 
deposition from an organic solvent and spreading on a large area as single or 
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multilayer (Figure11). The effect of fabrication process of polymer nanoparticle on 
devices was studied by Piok et al and reported that there is no significant difference 
in quantum yields for bulk and polymer nanoparticle states.62 In the study, single 
layer methyl substituted poly(para phenylene) dispersion in water based OLED was 
fabricated by spin coating methods and it was observed that emission and absorption 
spectra of CPN dispersion, CPN film and polymer bulk in organic solvent are not 
intensely different from each other.  
 
 
Figure 2.12. Schematic representation showing fabrication process of 
semiconducting polymer nanoparticles for optoelectronic applications.61 (Reproduced 
with the permission from ref 61. Copyrigth (2008) Royal Chemical Society) 
 
Another novel approach to LED applications was to generate white light via the 
tunability of emission color of CPNs containing cross-linkable functional groups.63 
Crosslinking enhances both the mechanical stability of polymer nanoparticles and 
forms a core shell structure which contains blue emitting layer in the core and 
yellow-green emitting layer in the shell. Through the energy transfer between these 
layers at different emissions wavelength with the control of the shell formation white 
light generation was obtained. 
Applicability of conjugated polymer nanoparticles in photovoltaic cells was reported 
by Sherf and coworker.64 The study is based on nanoparticle solar cell application 
through PFB and F8BT polymers which have high hole and electron mobility and it 
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was investigated that nanoparticles in photovoltaic cells provide controlling phase 
separation in polymer blend layer which effects to performance of the cell.  
 
2.2.3 Conjugated Polymer Nanoparticles in Nanomedicine 
Delivering of small molecules such as DNA, proteins and pharmaceuticals is one of 
the most important areas in the nanotechnology. Drug industries begin to give high 
attention to the novel drug carrier technologies. Recent developments in 
nanotechnology have provided new biological tools which are able to deliver 
pharmaceuticals in high efficiency, long time delivery and in a safe way of the drug 
loaded structures. Traditional therapeutic methods prepare only non-specific 
drugmixtures while these nano devices have important roles not only for drug 
delivery but also for molecular imaging and biomarkers.  
CPNs in bioimaging  
Molecular tracking of drug carriers plays a crucial role in target specific drug therapy 
because controlling biodistrubution of drug molecules is an important issue in drug 
delivery studies. In order to investigate spatial and temporal interactions of 
therapeutic agents with cellular compartments, bioimaging techniques have to be 
applied. Application of fluorescence technology in especially cell biology provides 
the enhancements in real time measurements in high sensitivity and high efficiency 
Therefore drug delivery science seek developments in fluorescence microscopy since 
1970’s.65 In the same aspect, application of live cell imaging has a significant 
potential for drug delivery research through providing the understanding of dynamic 
events, such as intracellular trafficking.66 Conventional fluorescent dyes have been 
used initially in this area but recent developments in the fluorescent nanoparticles 
made them significant candidate in imaging guided drug delivery. Encapsulation of 
organic dye with silica or polymeric nanoparticles are used in theranostic therapies 
due their mechanical stability and ability to amplify signal considerably. Significant 
advantages of encapsulation of dye with nanoparticles is to reduce photobleaching 
via polymer coating which penetrates the interaction with the oxygen.67-68 Quantum 
dots another bioimaging tools which provides extended visualization of cells under 
multicolor imaging. Quantum dots are semiconductor crystals in the nanometer size 
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with broad absorption and narrow emission spectrum and also tunability of emission 
spectra by controlling of their size. The best applicable quantum dots fluorophores 
for biological applications are CdSe coated with ZnS which protects core layer from 
oxidation and prevent photobleaching of the CdSe.69 Typical fluorescent imaging 
agents containing conventional dyes have photobleaching and toxicity problems. 
Although quantum dots have high brightness and photostability, they are cytotoxic  
due to heavy metals from their nanocrystal core and their biocompability is not high 
enough for biological applications. These limitations necessitates for the design of 
new fluorescent materials. One promising strategy is to develop fluorescent 
conjugated polymer materials which are useful sensing tools via the signal 
amplification. Several conjugated polymers have been used for live cell imaging due 
to their high brightness, good photostability and lower toxicity. One of them is 
reported by Wu and coworkers including new size controlled polymer dots from 
fluorene derivatives which exhibit much higher emission rate and no bleaching with 
respect to their conventional dye molecules70. It was investigated that these polymer 
dots are very promising for single molecule imaging and tracking of live cells due to 
their high absorption cross section, bright fluorescence and high photon numbers 
(Figure 12). Furthermore, cytotoxicity of the polymer nanoparticles was not in an 
appreciable extent givenresulting incubation time and concentration. 
 
 
Figure 2. 13. Differential contrast (top) and fluorescence (bottom) images of 
macrophage cells labeled with PFO PFBT polymer dots.70 (Reproduced with the 
permission from ref 70. Copyrigth (2008) American Chemical Society) 
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Targetted drug delivery via CPNs 
Nanoparticles improve the bio-availability of water- insoluble drugs,protect the drugs  
From physiological barriers and increase tolerability ofthe body to the drugs and in 
turn, this enhances the efficiency of drug delivery. However, although these 
nanocarriers increase the therapeutic index of drugs, they are generally simple and 
lack of efficient targeting and improved with the design of multifunctional 
nanoparticle platforms which enhances cell or tissue targeting. 
In principal, delivery of anticancer drugs by nanocarriers is achieved by active or 
passive targeting. In passive targeting long circulating nanoparticles accumulate 
passively on solid tumor tissue by enhanced permeability and retention effect (EPR). 
EPR effect is result of angiogenesis in tumor tissues. Blood vessels in tumor tissues 
have gaps with the sizes of between 600 and 800 nm.71-72 Passive targeting takes 
advantages of size of nanoparticles. Nanoparticles can enter the tissue through these 
defects and accumulate on tumor tissues. It has been demonstrated that 10 fold 
greater increase occurs in the drug accumulation on tumor tissue when drug is 
delivered by nanoparticles rather than as free drug.73 Passive targeting generally uses 
EPR effect and this delivery does not have an effective targeting and has some 
limitations of distribution of drug. Drug molecules can outflow from the cells due to 
osmotic pressure in the intervascular side and this prevents efficient distribution of 
drug molecules to the cancer tissue.74 These limitations in passive targeting can be 
alternated with the conjugation of targeting ligand or antibody to the nanoparticle. 
Ligand targeted approach is expected to deliver drug molecules in a high selectivity. 
75Active targeting is based on the ability of targeting agent to bind to tumor tissue 
surface to trigger receptor mediated endocytosis. A variety of tumor targeting ligands 
such as antibodies, growth factors or cytokines have been used as targeting agents.76-
77 In brief, efficient targeting is based on size, surface modification of nanocarriers 
and the presence of the targeting ligand.A novel targeted delivery of conjugated 
polymers is reported by Rong et al in which the design of conjugated polymer 
nanoparticles is based on fluorene and benzothiodiazole units containing boron 
dipyromethene (BODIPY).78 Highly bright and narrow emissive polymer dots which 
exhibit emission full width at half- maximum varying from 40-55 nm were obtained 
through the intra-chain energy transfer between the polymer and BODIPY units. 
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Cellular labeling with these highly fluorescent marker was demonstrated by 
fluorescence imaging and flow cytometry experiments.The bio-conjugation of 
streptavidin to the carboxylate functional groups of the nanoparticle surfaces through 
covalent bond linkage provides cell specific targeting based on interaction between 
biotinylated antibodies and streptavidin conjugated polymer nanoparticles (Figure 
13).  
 
 
Figure 2. 14. Schematic illustration of narrow emissive CPN bioconjugates for 
specific cellular targeting.78 (Reprinted with the permission from ref 78. Copyrigth 
(2013) American Chemical Society) 
Wang et a lreported a facile multifunctional drug delivery system consisting of a 
complex of positively charged conjugated polymer (PFO) with negatively charged 
poly(L-glutamic acid) (PG) loaded with the anticancer drug doxorubicin (DOX).79 
Conjugated Polymer (PFO) exhibited a high quantum yield and photostability. 
Delivering Dox to lung cancer cells and release process were monitored by using 
fluorescence signal of PFO. When PFO/PG-DOX complex was internalized by the 
cells, the PFO remained in ‘turn off’ state, however, after 24 hours bright 
fluorescence of PFO was observed inside the cells due to release of DOX and weak 
fluorescence of DOX also was seen (Figure 14).  
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Figure 2. 15. Light and fluorescence miscroscopy images of A549 cell after 
incubation with PFO/PG-DOX for (a) 0 and (b) 24 h and (c) the fluorescence 
recovery of PFO.79 (Reprinted with the permission from ref 79. Copyrigth (2010) 
American Chemical Society) 
 
Fernando and coworker investigated therate, efficiency and mechanism of uptake of 
PFBT polymer dots through the cell line, J774A, which have similarities with 
macrophages.80 To analyze the rate of nanoparticle uptakes, cells are incubated in 
different time scales and resulting intercellular fluorescence was measured by flow 
cytometry. It was also exhibited that the rate of nanoparticle uptake depends on the 
concentration of nanoparticle and temperature. The results indicate that very low 
amount of nanoparticles (155 pM) is enough for efficient labeling and low 
temperatures decrease the rate of uptake. Furthermore, live cell imaging highlights 
the entry routes of nanoparticles and their final locations in cellular compartments, it 
was hypothesized that endocytotic mechanism is responsible for PPFT dots uptake. 
The  routes of nanoparticles was determined by using specific cellular markers such 
as protein lysosomal associated membrane protein (LAMP-1) taken up by the 
membranes of late endosomes and remains in the lysosomes and it was confirmed 
that nanoparticles localized in LAMP-1 containing organelles. 
CPNs as nucleic acid therapeutics carriers 
Nucleic acid therapeutics are important tools to treat many diseases, especially 
cancer. Synthetic small interference RNAs (siRNA) are important class of nucleic 
acid therapeutics including gene silencing mechanism with 21-25 nucleotides which 
degrade target mRNA.81 siRNAs have significant therapeutic potential however 
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inefficient delivery systems due to stiff structure of siRNA limits their biomedical 
applications, thereby, a feasible and smart delivery systems should be developed to 
achieve a successful internalization by the desired tissue through protecting the 
stability of siRNAs in the body and facilitating cellular uptake.82 It was investigated 
that many cationic species can make polyelectrolyte complexes with negatively 
charged RNA through electronic interactions, hence this complex formation provides 
the protection of siRNA from extracellular enzymes and mild cellular uptake. 
Liposomes, lipids, peptides, polymers, virus based vectors have been studied as 
delivery carriers in order to improve the efficiency of targeted delivery, enhance the 
biodegradability of vesicles and increase the circulation time in the body. However 
severe toxic effects of cationic species result limitations in the clinical applications.83 
Recently, several hydrophobic compounds are tried to be incorporated into the 
delivery vesicles to increase the complexation efficiency and to decrease the toxicity. 
Conjugated polymers have high potential in the area of nucleic acid delivery due to 
their flexible side chains which can be substituted with positive charges enabling to 
attract negatively charged nucleic acids and rigid backbones which provides facile 
cellular uptake.84 Moon et al reported siRNA for actine B gene delivery to the HeLa 
cell via CPNs from amine containing poly(phenylene ethylene) through taking 
advantage of their low toxicity (Figure 15).85 Fluorescent visualization and 
significant down regulation of target protein was observed. Hence, it was 
investigated that polymer nanoparticles make stable complex with siRNAs due to 
their large surface area which is the result of hydrodynamic volume rather than solid 
form and showed that increase in hydrodynamic volume of nanoparticles also 
increases the efficiency of complex formation with siRNA. 
 
Figure 2. 16. Shematic representation of complex formation between poly(phenylene 
ethylene) CPNs and siRNA for actine B gene delivery.85 (Reprinted with the 
permission from ref 85. Copyrigth (1995) Royal Chemical Society) 
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Hydrophobic polymers have aggregated nature in a poor solvent, and this feature of 
polymeric nanoparticles can provide using them as efficient delivery agents after 
entrapping with nucleic acids derivatives. Zare and coworkers published a study of 
siRNA delivery which consist of encapsulation of hydrophilic nucleic acid tRNA  
into copolymer (L-lactic acid )-polyethylene glycol for sustained release in vivo. 86 
Nanoparticles were prepared through solution enhanced dispersion method with non-
toxic supercritical carbondioxide as anti-solvent which provides efficient 
encapsulation and protection of nucleic acids by the polymers. 
In vivo applications of CPNs 
Fluorescence imaging methods remain generally in vitro studies or small animal 
models and not improve to clinical applications due to limitations in absorbance, 
scattering and autofluorescence phenomena. However using near infrared (NIR) 
excitation is less harmful for biological samples resulting minimum photodamag and 
has greater sample penetration depths with minimum autofluorescence.87 However, 
there are several drawbacks in in vivo applications of conjugated polymer 
nanoparticles despite of their excellent brightness and nontoxic features. One of them 
is decreasing of their fluorescence quantum yield in red or NIR region through 
nanoparticle formation. Through this aspect, Kim et al developed water dispersed 
cyanovinylene-backboned polymer dots show bright fluorescence and synthesizing 
directly with in situ polymerization in the aqueous phase and showed their in vivo 
applications in a mouse model.88 Furthermore, chemical and mechanical stability of 
nanoparticles in bodily fluid and strong NIR suggest their utilizations in in vivo 
applications. As an another novel approach to obtain deep red emitting polymer dots 
for in vivo applications, Chiu and coworkers designed polymer blend nanoparticle 
system which is based on an intra-particle energy transfer between a light harvesting 
polymer (PPFT) as donor and an efficient deep red emitting polymer (PF-DBT5) as 
an acceptor.89 Fluorescence intensity distribution shows that fluorescence intensity of 
polymer blend dots is 15 times higher than QDs. Moreover, those polymer blend dots 
can be used to label specific cellular parts through polymer blend-streptavidin 
bioconjugate forms. 
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Caenorhabditis Elegans (C. Elegans) as model organisms for in vivo applications 
C. Elegans is a transparent soil nematode with well-defined anatomy which is 1 mm 
long as being adult and consist of invariable number of 959 cells. The most feasible 
feature of C. Elegans as model organism in biological applications is its completely 
sequenced genome which enables to study biological processes in molecular level. 
Moreover, being optically transparent allows to image whole organism and track 
biodistribution of fluorescent markers. Alternatively, C. Elegans provides easy 
handling with their short life cycles and analyzing the results of various type of stress 
factors due to their sensitivities to these stimulants.90-91 
In the area of bioimaging, several fluorescent markers were analyzed in vivo studies 
by using C. Elegans. For instance, Austin and coworkers published a preliminary 
work including imaging up-conversion phosphors (non-aggregated nanocrystals in 
the size of 50-200 nm) in the digestive systems in C. Elegans by using near infrared 
spectrum.92 Moreover, survival rate of organisms was analyzed over 6h and it was 
investigated that there is little toxic effects of these nanoparticles in the organisms. 
Another study about the biomaging through C. Elegans,which demonstrates the 
internalization of novel fluorescent nanodiamonds from nanocarbon family through 
the worms, was reported by Mohan et al.93 The nanodiamonds were introduced to 
both with microinjection into the gonads of the worms and with feeding method to 
investigate the interactions between the nanomaterial and C. Elegans. The toxicity 
assessments were applied by life span and reproductivity assays and it was reported 
that these nanomaterials are nontoxic and not cause any reasonable stress for the 
worms. Additionally, it was also showed that the treated worms exhibit similar 
feeding behaviour with untreated worms and nanodiamonds do not cause any defect 
in natural behaviours (Figure 16).  
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Figure 2. 17. Epifluorescence and epifluorescence/ DIC merged images of wild type 
C. Elegans A) untreated young adults, worms fed with fluorescent nanodiamonds for 
B) 2 h and C)12 h.93 (Reprinted with the permission from ref 85. Copyrigth (2010) 
Royal Chemical Society) 
Camptothecin as an Anti-Cancer Therapeutic  
(S)-Camptothecin(CPT) is a pentacyclic alkoloid which is isolated firstly by Wall 
and coworkers in 1966 and promising in clinic activities of cancer treatment due to 
its anti-tumor activity.94 The structure of the CPT is given in Figure 17. First total 
synthesis of CPT was reported by Stork and Shultz in 1971.95 CPT gained a 
significant attraction as anticancer drug and this leads to synthesize its water soluble 
analogs to improve therapeutic applications limited due to its insolubility in aqueous 
medium.Topotecan and irinotecan are FDA approval camptothecin analogs and used 
in ovarian, small cell lung, refractory colorectal cancer treatments.96 Primary cellular 
target of CPT is DNA topoisomerease I, a nuclear enzyme which modifies the 
topological state of DNA through breaking phosphodiester backbones of DNA. It 
was suggested that CPT binds non-covalently to topoisomerase I-DNA complex to 
break DNA strands upon replication to trigger cell death during the S-phase in the 
cell cycle.97 Targeted and controlled delivery systems were developed for 
theinternalization of CPT into the cancer cells. One of them is reported by 
Yokoyama et al, consisting of CPT loaded polymeric micelles based on 
poly(ethylene glycol)- poly(benzyl L aspartate-69) block copolymer.98 
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Figure 17. Structure of Camptothecin97  
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CHAPTER 3 
3.EXPERIMENT RESULTS 
 
3.1.  General 
All reagents were purchased from Sigma Aldrich Chemical Co. And were used as 
received. Column chromatography with silica gel (Kiegesel 60, 0.063-0.200 nm) was 
used for the purification of monomers. Thin layer chromatography (TLC) was 
performed by using silica gel plates (Kieselgel 60 F254, 1mm) to identify the 
products and impurities and determine the purity of the desired products. For 
structural characterization, nuclear magnetic resonance (NMR, Bruker Avance III 
400 MHz spectrometer ) and fourier transform infrared spectroscopy (FT-IR, Bruker 
Tensor 27) were performed. CDCl3-d6 solvent was used for NMR measurements. 
For the FT-IR measurements, KBr pellets were prepared. The data were recorded at 
25oC, in the spectral range of 4000-400 cm-1, by accumulating 25 scans with a 
resolution of 4 cm-1. For the optical characterization, a UV-Vis spectrophotometer 
(Cary Uv-Vis) and a fluorescence spectrophotometer (Cary Eclipse) equipped with a 
xenon lamp as the excitation source were used. Molecular mass of the monomers 
were determined via a liquid chromatography mass spectroscopy ( TOF LC/MS, 
Agilent 1200/6210). Autoclaved  ddH2O was used to prepare the nanoparticles. The 
sizes of nanoparticles were measured by dynamic light scattering (DLS, Zetasizer 
Nano-ZS). Measurements were carried out at 633 nm and the laser, as a light sources, 
was used at room temperature. The avarage particle diameters were calculated by the 
Marquardt method. The DLS measurements were usually repeated at least three 
times and the avarage values were reported. Morphological characterization was 
done by transmission electron microscopy (TEM, FEI Tecnai G2 F30) and scanning 
electron microscopy (SEM, Quanta 200 FEG). 
Preparation of cells and culture : Human Breast Adenocarcinoma cell lines MCF 7 , 
MDA-MB-231, MDA-MB-157 were maintained in Dubelcco’s Modified Eagle’s 
Medium (DMEM) (HyClone with 1000mg/L glucose, 4 mM L-Glutamine and 110 
mg/Lsodiumpyruvate).MTT (3-(4,5-dimethylthioazol-2-yl)-2,5-diphenyltetraazolium 
bromide (Sigma Alrich) was used for MTT cell proliferation assay. Cells were 
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incubated at 37oC with 5% CO2. DMSO (Sigma Aldrich) was used as solvent for 
camptothecin (Calbiochem) at a concentration less than 1% in the cell culture 
medium. In order to detect cell proliferation BrdU reagent (Sigma Aldrich B9285) 
was used with primer antibody BrdU mouse- mAB #5292S (Cell Signaling 
Technology) and seconder antibody anti-mouse IgG (H+L), F(ab’)2Fragment (Alexa 
Fluor 555 Conugate) #4409 (Cell Signaling Technology). To quantify the amount of 
adsorbed proteins on the nanoparticles in the human blood serum environment 
Bradford reagent (Coomasive blue G-250) was used and the absorbance values of the 
samples were obtained through a spectrometry at  595 nm (Beckman-DU 640). 
Zebrafish embryos were purchased from Wisconson Madison University (US) and 
kept through Bilgen Zebrafish Facility in Bilkent University, Department of 
Moecular Biology and Genetics. Zebrafish experiments were approved by Ethic 
Comittee in Bilkent University. C. Elegans were purchased from C. Elegans Stock 
Center.   
3.2 Syntheses of Monomers and Polymer  
3.2.1. Synthesisof 2,7-dibromo-9,9-bis-(6-bromo-hexyl)-9H-fluorene (M1) 
2,7 Dibromofluorene (2.0 g, 6,17 mmol) and tetrabutylammoniumbromide (0.40 g, 
1.20 mmol) were dried under vacuum and nitrogen for 30 min. DMSO (10 ml) which 
was degased with Argon was added to the solid mixture. To this mixture, degassed 
DMSO (15ml), 50% NaOH (15 ml) and 1,6 dibromohexane (9.5 ml, 60 mmol) were 
added, respectively. The resulting mixture was stirred at room temperature for 2 
hours. Work-up was done with diethyl ether (125 ml) and water (50 ml) to the 
reaction. The reaction was exothermic and an ice bath was needed to control the 
temperature. For the work-up, the organic layer was extracted in diethyl ether and 
washed with 1x100 ml water, 1x2N HCl 100 ml, 1x100 ml water, 4x100 ml brine 
solution, 3x100 ml water. The diethyl ether was removed under reduced pressure. 
Vacuum distillation was applied to the liquid product in order to remove DMSO. The 
final product was purified with column chromatography packed with silica using 
cyclohexane as an eluent. For further purification, the desired monomer was 
dissolved in minimum amount of cyclohexane and precipitated into cold methanol, 
filtered and dried under vacuum. Yield: 1.62g 40 %. 
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1H-NMR (400 MHz, CDCl3, δ ppm):7.5 (m, 6H), 3.30 (t,4H), 1.87 (t,4H), 1.79 (t, 
4H), 1.22 (t,4H), 1.12 (t,4H), 0.61 (t, 4H) 
13C-NMR (400 MHz, CDCl3, δ ppm):144.1, 140.1,135.5, 132.2, 130.1, 129.8, 122.5, 
43.5, 42.9, 32.9, 34.1, 29.9, 28.1, 23.1. 
 
3.2.2. The Synthesis of {6-[2,7-Dibromo-9-(6-dimethylamino-hexyl)-9H-fluoren-
9-yl]-hexyl}-dimethyl-amine 
2,7-Dibromo-9,9-bis(6-bromo-hexyl)-9H-fluorene (M1)(1.00g,1.54 mmol) was 
dissolved in dry THF (5 ml) and flushed with argon. The solution was cooled down 
to -78oC. 2 M solution of dimethylamine in THF was added under argon. The 
mixture was brought to room temperature and stirred for 24 hours at room 
temperature. THF was removed under reduced pressure and 0.1 M NaOH (5 ml) and 
chloroform (10 ml) were added. The mixture was stirred for 30 minutes and organic 
layer was separated and washed with 50 ml brine solution. The solvent was removed 
under reduced pressure to obtain an oily solid in which water was added and the 
suspension was stirred for 10 min and the precipitateswere collected through suction 
and dried. The yield is 0.71 mg, 80 %. 
1H-NMR (400 MHz, CDCl3, δ ppm): 7.55 (m,6H), 2,17 (t, 4H), 1.95 (m,12H), 1.28 
(m,4H), 1.09 (m,8H), 0.61 (t,4H) .                 
13C-NMR (400 MHz, CDCl3, δ ppm):141.1, 135.5, 132.2, 129.8, 122.5, 58.6, 43.5, 
42.9, 41.5, 30.6, 29.4, 28.0, 25.1.  
TOF-MS: [M2]+m/z : 579.17 
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3.2.3. Synthesis of Poly[(9,9-bis{6-dimethylaminohexyl}fluorenyl-2,7-diyl)-co-
(1,4-benzo-{2,1,3}-thiodiazole)] (PDAFBT) 
{6-[2,7-Dibromo-9-(6-dimethylamino-hexyl)-9H-fluoren-9-yl]-hexyl}-dimethyl 
amine (500 mg, 0.864 mmol), 2,1,3-Benzothiadiazole-4,7-bis(boronic acid pinacol 
ester) (307.404 mg, 0.864 mmol), Pd(Ph3P)4 (17.68 mg, 0.0153 mmol) and K2CO3 
(625 mg, 4.513 mmol) were placed in a 25 ml round-bottom flask an dried under 
vacuum remove for about 30 min. Then, degassed THF (8 ml) and water (5 ml) were 
and added to the reaction vessel under argon and freeze-pump-thaw method was 
applied three times for further removal of the oxygen. The mixture was stirred at 
80oC for 5 h under argon. After cooling to the room temperature, the mixture was 
diluted with chloroform and water. The insoluble part was removed by filtering 
through glass filter funnel and soluble part was redissolved in THF and precipitated 
into water. The solid residue was washed again with deionized water. The orange 
precipitates were collected by suction and dried under vacuum. Yield : 0.2g, 25 %. 
1H-NMR (400 MHz, CDCl3, δ ppm):7.6-7.7 (m,6H), 7.5 (m,2H), 2,36 (m, 4H), 2.27 
(m,12H), 1.39 (m,4H), 1.29 (m,8H), 1.87 (m,4H) .                 
13C-NMR (400 MHz, CDCl3, δ ppm):156.4, 154.0, 142.4, 141.8, 137.1, 136.0, 135.4, 
133.5, 130.2, 129.6, 128.4, 127.8, 127.2, 126.7, 58.6, 45.5, 42.9, 41.5, 30.6, 29.4, 
28.0. 
FT-IR (KBr, pellet,υmax(cm-1)): 3074(-C-H, m), 2918 (-C-H,s), 1500 (-C-C in ring, 
m), 1265 (-C-N, m). 
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3.2.4.Synthesis of PDAFBT Nanoparticles  
PDAFBT (2.0 mg, 3,6 10-3 mmol, based on per repeat unit) was dissolved in THF 
(5ml) then solution was filtered through syringe filter (0,45μm PFFT) and sonicated 
for 30 min. The resulting solution was injected rapidly into the autoclaved double 
disttiled water (50ml) in the ultrasonic bath. It was stirred for further 30 min. THF 
was removed under reduced pressure. The resulting nanoparticle solution was 
concentrated under reduced pressure to obtain the desired concentration for the 
experiments.  
3.2.5. Synthesis of Drug Loaded PDAFBT Nanoparticles and Determination of 
Drug Loading Capacity of PDAFBT Nanoparticles 
For the drug loaded nanoparticles preparations drug to polymer ratios were selected 
as 1:10, 1:25, and 1:35, weight to weight (w/w). To prepare the drug loaded 
nanoparticles for the 1:10 (drug to polymer) ratio, 2.0mg (3.6 x 10-3 mmol, based on 
per repeat unit) of PDAFBT and 2.0 x10-1mg CPT (5.7 x 10-4 mmol) was dissolved 
in 5 ml of THF and for the 1:25 (drug to polymer) ratio, 2.0 mg (3.6 x10-3 mmol, 
based on per repeat unit)  of PDAFBT and 8.0 x10-2mg CPT (2.3 x 0-4 mmol) was 
dissolved in 5 ml of THF. In the similar manner, to prepare for the 1:35 (drug to 
polymer) ratio, 2.0 mg (3.6 x10-3 mmol, based on per repeat unit) of PDAFBT and 
5.5x10-2 mgCPT (1.6 x 10-4 mmol) was dissolved in 5 ml of THF. The resulting 
solutions were sonicated for 30 min and injected into the autoclaved double distilled 
water (50ml) in the ultrasonicbath. They were stirred for further 30 min. THF was 
removed under reduced pressure. The resulting nanoparticle dispersions were 
transferred into a dialysis tube (cellulose tubular membrane, 3.47 mm,Cellu Sep) 
with molecular weight cut-off 3000 Da and dialyzed against water for 24 hours at 
29 
 
room temperature while providing a gentle stirring. After 24 hours,the dialysates of 
each set of experiments were evaporated to dryness and the remaining residues 
weredissolved in 3 ml of THF. Subsequently, the concentration of CPT in the release 
medium was measured by using absorption spectroscopy (λex= 366 nm). As a control 
experiment, the dialysis of free CPT was carried out by keeping the concentration of 
CPT as the same as used in the drug-loaded nanoparticle cases. 
3.2.6. Drug Release Study  
To determine the drug release profile of the CPT encapsulated nanoparticles, the 
drug-loaded nanoparticles with the drug to polymer ratio of 1:35, w/w was prepared 
and the solution was concentrated down to 2 ml and the final volume was made upto 
10 ml with 10 M PBS solution. This solution was transferred into a dialysis tube 
(cellulose tubular membrane, 3.47 mm, Cellu Sep) with molecular weight cut-off 
3000 Da. The dialysis tube was placed into a beaker containing 100 ml of PBS buffer 
and 2% Tween 20 and dialyzed at 37oC while shaking at 60 RPM. 1ml of aliquots 
were withdrawn from the medium at different time intervals during 50 hours time 
period and at each time, equal amount of fresh PBS was added to the release medium 
to prevent the sink condition.The concentration of CPT in the release medium was 
measured by using absorption spectroscopy (λex= 366 nm). 5 samples at known 
concentrations in THF were used to obtain a calibration curve to determine the 
concentration of unknown sample. 
3.2.7.  Sample Preparation from PDAFBT Nanoparticles for TEM imaging  
Negative staining with phosphotungstic acid to PDAFBT nanoparticle dispersions 
(7.2 10-5M) was donein order to obtain TEM images. Nanoparticle-phosphotungstic 
acid solution was prepared in the 8:1 ratio from 1 % (w/w) solution of 
phosphotungstic acid in distilled water. 15 ul was taken and dropped onto the surface 
of the grid. After waiting for adhesion of the nanoparticles on the surface in 5 
minutes, drop was removed from the surface. After the complete dryness of sample 
on the grid, the images were taken. 
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3.2.8. Preparation of PDAFBT Nanoparticle Solutions in Bovine Serum 
Albumin and Human Serum Media  
PDAFBT (2.0 mg, 3,6 10-3 mmol, based on per repeat unit) was dissolved in THF 
(5ml) then solution was filtered through syringe filter (0,45μm PFFT) and sonicated 
for 30 min. The resulting solution was injected rapidly into the autoclaved double 
disttiled water (50ml) in the ultrasonic bath. It was stirred for further 30 min. THF 
was removed under reduced pressure. The resulting nanoparticle solution was 
concentrated under reduced pressure to 22.5×10-5 M with three replications. Then 
concentrated PDAFBT nanoparticle solutions were rediluted with stock solutions of 
bovine serum albumine (BSA) ( 10 mg in 10 ml of water) and human serum (10% 
(v/v)) to 7,2x10-5M. Prepared nanoparticles solutions were incubated at 37oC and 60 
RPM  and 1 ml of aliquotes were taken at 0, 30 and 120 min time periods to measure 
their size by DLS. 
3.3 Biological Assays  
3.3.1.3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT) In 
Vitro Toxicology Assay for Culture Cells Treated with Blank and Drug Loaded 
Nanoparticles 
MCF-7, MDA-MB-231, MDA-MB-157 cell were inoculated (2000 cells /well in 300 
μL) in 96 well plates. The next day, the media were refreshed and the CPT and CPT 
loaded PDAFBT nanoparticles were placed in the range of concentration between 
0,125 and 2μM in parallel with DMSO-only and CPN-only treated cells as negative 
controls. At the end of 48 h of treatment resulting cells were treated with MTT 
reagent for 4 h at 37oC  then after treating with Sodium Dodecyl- HCl was treated 
cell were incubated 18h at 37oC . After incbation well plate was shaken and the 
absorbance values were obtained through microplate reader at 570 nm. 
3.3.2. 5-Bromo-2-deoxyuridine (BrdU) Cell Labeling and Proliferations Assay 
for Culture Cells Treated with Blank and Drug Loaded Nanoparticles 
MCF-7 cells were inoculated (100000 cells / well in 1000 μL) in 6 well plates and 
treated with blank PDAFBT nanoparticles (30μM, concentration of 2μM CPT loaded 
nanoparticles) 48h later, BrdU reagent (12μL for 12 mL DMEM) was treated with 
the cells for 2h. After the exposure time, the cells were washed with phosphate buffer 
saline (PBS) (0.02M) and fixed with slowly added methanol (in -20oC) after 10 min 
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cells were washed with PBS again. Washed cells were exposed to HCl (2N) for 30 
min at 37oC then add with borate buffer and washed PBS (0,03 M). After 30 min 
primary antibody (α-BrdU) diluted in blocking solution was apllied for 1h. After 
exposure, cells were washed with %0.5 tween 20 containing PBS (PBS-T) 3 times 
then secondary antibody diluted in PBS-T only  was treated for 2h washed again 
PBS-T 3 times.After treatments, cell were placed onto the slide with mounting 
medium with DAPI and cells screening under the fluorescence microscope through 
the blue, red and yellow filters at 40X magnification. 
3.3.3. Bradford Protein Assay to Determine the Quantitative Amount of Human 
Plasma Proteins Adsorbed on the Surface of Nanoparticles 
Bradford reagent without protein (900 μL), 98 μL ddH2O and 2μL human plasma 
serum (1X) at the 0.5 X, 0.25X, 0.125X, 0.0625X dilutions were prepared as 
reference solutions, and the intensityof absorbance was read at 595 nm through a 
spectrometer. Human plasma serum added nanoparticles solution was precipitated 
through centrifugation at 4000 rpm for 15 min and washed with ddH2O three times. 
Then, 2 μL of nanoparticles dispersion (0,8 μg in 2 ml water) was mixed with 
bradford reagent (900 μL) and 98μL and their intensity of absorbance  read at 
595nm.  
3.3.4 PDAFBT Nanoparticle Staining Protocol on Embryonic Zebra Fish  
0.5 and 2 μM CPT loaded and blank PDAFBT nanoparticles prepared in the system 
of used for zebrafish maintanence at BILGEN Bilkent University Department of 
Molecular Biology and Genetics. Zebra fish embryos (48h postproliferation, hbf) 
were kept in these nanoparticle medium at 28oC for 24h. After treatment embryos 
were fixed with 4% paraformaldehyde for 48h then washed with PBS-t  two times. 
After washing, fixed embryos were treated with glycerol (50%)  for 30 min at 4oC 
then transferred onto a microscope slide and slide was covered with a coverslip and 
the periphery of it was sealed with a nail polish. Prepared slides were checked under 
fluorescence microscope with multidimensional acquisition under GFP lamb.  
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3.3.5 PPFBT Nanoparticle Staining protocol on C. Elegans  
Synchronized worms at L4 stages in the plates were washed with  10 ml of phosphate 
buffer salinebuffer (PBS (1X) and spun in the centrifuge at 2500 RPM for 2 min. 
Supernatant was taken and washing step was replicated three times then worms were 
re-suspended in 1ml of 0.01 mM PPFBT nanoparticle solution in PBS  buffer  during  
30 min. Then worms were settled down in centrifuge at 2500 RPM for 2 min. 
Stainingsolution was aspirated and pellet of worms washed three times with PBS 
buffer. In order to fix the worms, 1 ml of cold methanol (100%) was exposed for 5 
min. 600 μL of  PBTw (PBS containing 0.1 % tween-20) was added and the resulting 
solution was spun in the centrifuge at 2500 RPM. Supernatant was aspirated then 
worm pellets were washed with 500 μL of PBTw. Settled worms were transferred 
onto a microscope slide using a capillary pipette and after removing excess liquid 
with a tissue paper, slide was covered with a coverslip and the periphery of it was 
sealed with a nail polish. Prepared slides were imagedunder a fluorescence 
microscope with multidimensional acquisition under GFP lamb.  
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CHAPTER 4 
4.  EVALUATION 
 
This chapter consists of two parts. In the first section, synthesis and characterization 
of monomers and polymer are discussed. The second section reports the preparation 
of blank and drug loaded nanoparticles, their modifications and characterizations as 
well as their biomedical applications including stability tests in different biological 
media, toxicological analysis through cell culture studies, in vitro and in vivo 
imaging for different cell lines and different model organisms. 
The content of thesis work is illustrated in Figure 4.1. 
 
Figure 4. 1.Schematic illustration of thesis work. 
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4.1. Synthesis and Characterization of Monomers  
4.1.1.Synthesis and Characterization of 2,7-dibromo-9,9-bis-(6-bromo-hexyl)-
9H-fluorene (M1) 
2,7-dibromo-9,9-bis-(6-bromo-hexyl)-9H-fluorene (M1) was synthesized from 2,7-
dibromofluorene by removing the weakly acidic hydrogens at the C9 position with 
50% (w/w) NaOH solution. After the abstraction of mentioned protons, nucleophilic 
susbstitiution of 1,6-dibromohexane was achieved (Scheme 4.1). Due to addition of 
NaOH in aqueous phase, interaction between the aqueous and the organic phases was 
enhanced by the phase transfer catalyst tetrabutylammonium bromide (TBAB). 
Moreover, temperature control is important because the substitution and elimination 
reactions might be in competition in this reaction and to decrease the probability of 
elimination reaction leading to side products, reaction has to be conducted at room 
temperature. In order to prevent temperature raising due to addition of NaOH, the 
reaction vessel was kept in an ice bath during the addition of base. The isolation of 
the product was achieved by the extraction with diethyl ether, distilled water and 2N 
HCl (aq) followed by column chromatography (cyclohexane as eluent). M1 was 
obtained in white powders with 40% yield.  
BrBr
Br
Br
50% NaOH (aq)
DMSO, TBAB
2h, RT, 40%
BrBr
Br Br  
Scheme 4.1 Synthesis mechanism of the monomer 2,7-dibromo-9,9-bis-(6-bromo-
hexyl)-9H-fluorene (M1). 
The structural characterization of the monomer M1 was done by 1H-NMR and 13C-
NMR spectroscopies shown in the Figure 4.2. In the 1H-NMR spectrum, the 
integrations and the chemical shifts of the peaks confirm the expected structure. A 
multiplet at 7.5 ppm belongs to the fluorene rings protons and triplet at 3.30 ppm is 
due to –CH2 protons adjacent to bromine which is relatively downfield shifted 
comparing to the rest of the methylene protons of the alkyl chain because ofthe effect 
of electron withdrawing bromine atoms. In the 13C-NMR spectrum peaks at between 
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the 122.5 and 144.1 ppm were observed due to carbons in the aromatic part of 
fluorene and peaks in the upfield region belong to the carbon atoms of alkyl chain 
(122.5, 43.5, 42.9, 32.9, 34.1, 29.9, 28.1, 23.1 ppm) and are in convenience with the 
expected  structure. 
(a) 
 
Figure 4.2. (a) 1H-NMR (400 MHz, CDCl3, 25oC) and (b)13C-NMR (400 MHz, 
CDCl3, 25oC) spectra of 2,7-dibromo-9,9-bis-(6-bromo-hexyl)-9H-fluorene (M1). 
* Denotes solvent peak and other impurities from the solvent. 
4.1.2.The Synthesis and Characterization of The Synthesis of {6-[2,7-Dibromo-
9-(6-dimethylamino-hexyl)-9H-fluoren-9-yl]-hexyl}-dimethyl-amine (M2) 
{6-[2,7-Dibromo-9-(6-dimethylamino-hexyl)-9H-fluoren-9-yl]-hexyl}-dimethyl-
amine (M2) was obtained through amination reaction of (M1) as shown in the 
Scheme 4.2.Since dimethylamine is highly reactive, the reaction was carried out at 
low temperature during its addition and after the addition was over the mixture was 
stirred at room temperature for 24h. The isolation of the product was done through 
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the extraction with chloroform and aqueous NaOH solution was used to neutralize 
the reaction mixture.After the removal of solvent, an oily solid residue was obtained 
in which water was added to obtain precipitates. Precipitates were collected by 
suction and dried under vacuum to obtain a yellowish powder with the yield of  80 
%. 
N
H in 2M THF BrBr
24 h , RT, under Ar
80 %
NN
BrBr
Br Br  
Scheme 4.2. Synthesis mechanism of the monomer {6-[2,7-Dibromo-9-(6 
dimethylamino-hexyl)-9H-fluoren-9-yl]-hexyl}-dimethyl-amine (M2). 
The structural characterization of the monomer M2 was done by 1H-NMR,13C-NMR 
spectroscopies and mass spectroscopy (TOF-MS) shown in the Figure 4.3 and Figure 
4.4. In the 1H-NMR spectrum, the integrations and the chemical shifts of the peaks 
confirm the expected structure. The 1H-NMR of monomer M2 differentiates from 
M1 through the disappearance of the peak at 3.30 ppm which belongs to –CH2  
protons near bromine due to replacing of –Br with -N(CH)2 group. Differently, 
chemical shifts of protons in (-N-CH3) group was observed as a multiplet at 1.95 
ppm and protons in (-N-CH2) was shown as triplet at 2.17 ppm. In the 
13C-NMR 
spectrum, chemical shifts between the 122.5 and 144.1 ppm were observed due to 
carbons in the aromatic part of fluorene. Chemical shifts at 41.5 ppm and 58.6 ppm 
belong to methylene carbons of dimethylamine group and carbons at CH2-. Other 
signals are similar with the monomer M1 and confirm the expected structure. 
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Figure 4.3. (a) 1H-NMR (400 MHz, CDCl3, 25oC) and (b) 13C-NMR (400 MHz, 
CDCl3, 25oC) spectra of {6-[2,7-Dibromo-9-(6-dimethylamino-hexyl)-9H-fluoren-9-
yl]-hexyl}-dimethyl-amine (M2). *Denotes solvent peak and other impurities from 
the solvent. 
The molecular mass of M2 was determined by using time of flight mass spectroscopy 
(TOF-MS). This method determines the mass to charge ratio of ions by measuring 
the traveling time for the distance to the detector under an electric field. Basically, 
this time depends on mass to charge ratio, namely heavier particles have low 
acceleration. For these large molecules, due to fragmentation many different ions can 
be formed but relative molecular mass of the molecule can be obtained. In the TOF-
MS spectrum of M2 given in the Figure 4.4, the peak at 579.17 indicates the 
presence of molecular ion of M2 confirming the expected structure. 
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Figure 4.4. TOF-MS spectrum of M2. ( m/z [M2]+ : 579.17) 
 
4.1.3. Synthesis and Characterization of Poly[9,9-bis{6-dimethylaminohexyl} 
fluorenyl-2,7-diyl)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PDAFBT) 
The polymer PDAFBT was synthesized through the Suzuki Coupling reaction of {6-
[2,7-Dibromo-9-(6-dimethylamino-hexyl)-9H-fluoren-9-yl]-hexyl}-dimethylamineas 
alkyl halide and 2,1,3-benzothiadiazole-4,7-bis(boronic acid pinacol ester) as 
organoboronic compound under Pd(Ph3P)4 catalyst which is given in the Scheme 4.3. 
Reaction has to be conducted under inert atmosphere because in the presence of 
oxygen, palladium catalyst can be oxidized readily and reaction do not start. The 
reaction time was kept relatively short in order to prevent high molecular weight 
polymer formation as the high molecular weight could be difficult to dissolve and 
process. Moreover, in order to obtain smaller nanoparticles low molecular weight 
polymer might be suitable. The polymer was isolated and purified by the by 
precipitation polymer solution in THF to water. The product was obtained as orange 
powder with 25% yield.PDAFBT was characterized by 1H-NMR, 13C-NMR, ESI-
MS,MALDI, FT-IR, UV-Visand Fluorescence spectroscopies. 
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Scheme 4.3. The synthesis mechanism of poly[9,9-bis{6-dimethylaminohexyl} 
fluorenyl-2,7-diyl)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PDAFBT). 
In the 1H-NMR spectrum of PDAFBT, it was observed that signals become more 
broader than 1H-NMR spectra of the monomers because monomer units are 
converted into long chains in which the mobility of the whole molecule is reduced. 
Signals observed at around 8.2 ppm as multiplets and 7.5 ppm as triplet are for 
aromatic protons of fluorene and benzothiodiazole units. The multiplets at 2.1 ppm 
are due to the protons –CH2-N and methylene protons belonging to the 
dimethylamine groups. Resonance peaks at 0.79 and 1.59 ppm belong to the proton 
of the alkyl chain in the polymer. In the 13C-NMR spectrum, chemical shifts between 
the 122.5 and 156.2 ppm were observed due to carbons in the aromatic part of 
fluorene. Chemical shifts at 41.5 ppm and 58.6 ppm and belong to methylene 
carbons of dimethylamine group and carbons at -CH2.  
Molecular mass of the PDAFBT was determined through electrospray ionization 
mass spectroscopy (ESI-MS) which applies soft ionization technique to produce 
charged gaseous species without causing high level of structural destruction for large 
biomolecules and synthetic polymers. In the spectrum given in the Figure 4.6 most 
intense peaks at 1683.2 and 1331.5 m/z indicate mainly the presence of dimer and 
trimer, respectively. However, in this technique it is not so possible to see molecular 
masses higher than 3000 even increasing the voltage because it is difficult to ionize 
larger molecules. Matrix-assisted laser desorption ionization mass spectroscopy 
(MALDI) is another useful analytical tool which gives mainly accurate m/z ratio 
values with efficient energy transfer during matrix assisted laser induced desorption 
process. The spectrum given in the Figure 4.6(b) indicates that m/z ratio of PDAFBT 
concentrates mainly in the region up to 4000 Da. ESI-MS and MALDI-MS results 
show that number of repeating units of the PDAFBT is around 5. 
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Figure 4.5. (a) 1H-NMR (400 MHz, CDCl3, 25oC) and (b) 13C-NMR (400 MHz, 
CDCl3, 25oC) spectra of Poly[9,9-bis{6-dimethylaminohexyl} fluorenyl-2,7-diyl)-
co-(1,4-benzo-{2,1,3}-thiodiazole)] (PDAFBT).*Denotes solvent peak and other 
impurities from the solvent 
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Figure 4.6. (a) ESI-MS of PDAFBT m/z [3M2]+ =1683.8 (b) MALDI-MS of 
PDAFBT m/z [2M2]+ =1331.5 (c) MALDI-MS of PDAFBT in the wide spectrum. 
 
FT-IR spectrum of the polymer PDAFBT is shown in the Figure 4.7. Spectrum 
shows peaks at 3074 cm-1 and 1500 cm-1 which belong to C-H and C-C stretching in 
the ring. The characteristic peak of C-N for aliphatic amines was shown at 1265 cm1. 
Optical properties of PDAFBT were determined by UV-Vis absorbance and 
fluorescence spectroscopiesand their absorption and emission spectra are shown in 
the Figure 4.8. The maximum absorption bands at 320 nm 446 nm and the maximum 
fluorescence emission band at 541 nm were observed in the region  of green light. 
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Figure 4. 7. FT-IR spectrum of poly[9,9-bis{6-dimethylaminohexyl}fluorenyl-2,7-
diyl)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PDAFBT). 
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Figure 4.8. UV-Vis absorption and fluorescence emission spectra of poly[9,9-bis{6-
dimethylaminohexyl}fluorenyl-2,7-diyl)-co-(1,4-benzo-{2,1,3}-thiodiazole)] 
(PDAFBT) in THF. (λex= 446 nm) 
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4.2. Synthesis and Characterization of Blank and Drug Loaded Water 
Dispersible Conjugated Polymer Nanoparticles (CPNs) 
Blank and drug loaded conjugated polymer nanoparticles were prepared through 
reprecipitation method. Polymer solution was dissolved in a relatively low amount of 
THF which dissolves the polymer well then this hydrophobic polymer solution 
rapidly injected during the sonication into excess amount of water which is a poor 
solvent for the polymer. This leads to collapse of polymer chains in order to decrease 
the contact area with water due to hydrophobic effect. After the removal of THF 
under reduced pressure spherical polymer dots were obtained. The characterization 
of nanoparticles was done by DLS and Zeta Potential to determine their size and 
stability. UV-Vis and Fluorescence spectroscopies are used to reveal their optical 
properties and their morphologies and sizes were investigated by SEM and TEM. 
4.2.1. Synthesis and Characterization of poly[9,9-bis{6-dimethylaminohexyl} 
fluorenyl-2,7-diyl)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PDAFBT) Nanoparticles  
In the preparation of PDAFBT nanoparticles, polymer solution was dissolvedin 
minimum amount of THF to obtained concentrated polymer solution and sonicated 
for 30 min, then the resulting polymer solution was injected rapidly into double 
distilled water. It was stirred with sonication for further 30 min. THF was removed 
under reduced pressure. For different experiments which will be mentioned further, 
different concentrations of nanoparticle solutions were adjusted by removing water. 
 
Figure 4.9. Cartoon representation of the preparation of PDAFBT nanoparticles. 
 
Particle size is an important information about nanoparticles which could affect the 
biodistribution in tissues. Mean particle size, the homogenity of the distribution of 
nanoparticles and the zeta potential values were determined by DLS and zeta sizer 
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which measures the random motion of particles due to effect of solvent molecules 
and relates this measurement averagely with the size of nanoparticles. The number 
average size distribution of nanoparticles were measured as 24 nm, shown in the 
Figure 4.10a. Polydispersity index is the parameter which shows homogenity of the 
size distribution. PDI values from 0.1 to 0.25 indicates narrow distributions and 
values greater than 0.5 shows broad distribution. In the following result, PDI index 
of 0.29 shows that size distribution of PDAFBT nanoparticles is nearly broad. Zeta 
potential value is obtained through the evaluation of electrophoretic mobility of 
nanoparticles dispersion in the medium and shows the ionic strength and colloidal 
stability of dispersion. Zeta potential values more positive than +30 mV and more 
negative than -30 mV indicates that nanoparticle solution are stable enough due to 
the repulsive forces. Zeta potential value of +35.5 given in the Figure 4.10.b  is the 
result of partial positive charge on dimethylamine groups of the polymer and shows 
that nanoparticle dispersion have colloidal stability. 
 
Figure 4.10. (a) Number avaragesize distrubution by histogram from DLS 
masurement and (b) zeta potential measurement of PDAFBT nanoparticles. 
It is possible to adjust the size of the nanoparticles by changing concentration of the 
polymer. To investigate that, different amount of polymers containing 1.25, 2.5 and 5 
mg was dissolved in the same amount of THF (5ml) and injected into the same 
volume of water (50 ml). It was observed that, as concentration of polymer increases 
from 1.25 mg to 5 mg, size of the nanoparticles doubles from 34nm to 62 nm (Table 
1), because polymer chains in more dilute solution were solvated much better by 
water molecules than in concentrated solution and hydrophobic effectprocesses more 
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efficiently in dilute polymer solutions. It was also observed that zeta potential values 
of nanoparticles do not indicate concentration dependent trend. Another important 
parameter which effects the size of nanoparticles is sample preparation.The results 
can vary even though using the same method due to aggregations. Obtaining well 
dispersion by sonication before the measurement affects the DLS result. This detail 
highlights differences of size and zeta potential values between two measurements of 
the same samples given in the following table (Table 1). 
 
 
Table 1. Number average size and zeta potential values of PDAFBT nanoparticles  at 
different polymer concentrations. 
Optical properties of PDAFBT nanoparticles were determined by UV-Vis and 
fluorescence spectroscopies and compared with the polymer solution in THF given in 
the Figure 4.11.  Maximum absorption peaks were observed at 317 nm and 444 nm 
for polymer solution in THF. While converting polymer into nanoparticle absorption 
wavelengths do not change significantly (1-3 nm red shift), however, 10 nm red shift 
was observed in the fluorescence emission spectrum  upon the formation of 
nanoparticles from the polymer. The red shift in the emission wavelength shows the 
collapse of polymer chains which leads to 𝝅- 𝝅 stacking, decrease in the band gap 
and lower in the energy.  
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Figure 4.11. UV-Vis absorption and fluorescence emission spectra of PDAFBT in 
THF (λex= 446 nm) and dispersion of PDAFBT nanoparticles in water (λex= 446 
nm). 
Microscopic techniques give precise information about the size, morphology and the 
state of aggregation of the nanoparticles.Morphological characterization of PDAFBT 
nanoparticles was done by SEM and TEM methods. Their micrographs are shown in 
the Figure 4.12 which indicate the formation of spherical polymer dots. It was also 
noted that the sizes of nanoparticles observed in the SEM and TEM are in good 
agreement with the DLS results. 
 
Figure 4.12. (a) SEM (b) TEM images of PDAFBT nanoparticles. 
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4.2.2 Synthesis and Characterization of Drug Loaded poly[9,9-bis{6-dimethyl 
aminohexyl}fluorenyl-2,7-diyl)-co-(1,4-benzo-{2,1,3}-thiodiazole)](PDAFBT) 
Nanoparticles  
Drug loaded nanoparticles were synthesized with the similar method used in 
preparation of blank nanoparticles. Camptothecin (CPT) was used as a model 
anticancer therapeutic to investigate the drug carrying ability of PDAFBT 
nanoparticles. CPT was encapsulated into polymer nanoparticles through 
hydrophobic interaction. PDAFBT and CPT dissolved in THF and injected into 
rapidly to the excess amount of water. During this addition, hydrophobic CPT tends 
to escape from water droplets and is encapsulated by collapsed polymer chains.  
4.2.3 Determination of the Drug Encapsulation Efficiency of PDAFBT 
Nanoparticles  
In order to investigate the drug encapsulation efficiency of PDAFBT nanoparticles,at 
different polymer to drug ratios including 1:15 and 1:25 were selected. Forthis 
purpose,dialysis membrane diffusion method was used. The amount of the non-
encapsulated drugs which is diffused out of the dialysis tube into the dialysate was 
measured after dialyzing the drug loaded nanoparticle for 24h at room temperature( 
Figure 4.13). 
 
Figure 4.13. Schematic representation of the study about determination of drug 
encapsulation efficiency. 
The theory of the study is based on the tendency of decreasing the concentration 
gradient of drug molecules through the diffusion from the membrane to the release 
medium. Drug loaded nanoparticles are not able to pass through the membrane due 
to their size. 
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Before analysis of the drug loading capacity of PDAFBT nanoparticles, molecular 
diffusion of CPT was tested by placing only CPT dispersion in water in the 
membrane and its release medium was quantitatively analyzed by UV-Vis 
spectroscopy after 24h. It was observed that whole of the CPT was diffused from the 
membrane into the release medium. Dialysis membrane and the release medium are 
two different environments and in order to lower the concentration gradient, CPT 
molecules have to diffuse from the membrane to the release medium. The volume of 
water in the membrane is 5 ml while the volume of water in the release medium 
being 100 ml. It means 5% of CPT has to remain in the membrane while 95% of 
CPT diffuses to the higher volume to obtain equal chemical potentials. It was 
calculated nearly 100% of CPT was diffused out of the membrane. The results are 
given in the Figure 4.13 and Table 2.5% error was observed maybe due to little 
differences in volumes of THF during the UV-Vis absorption measurements. 
(a)                                                    (b) 
 
Figure 4.14. UV-Vis absorption spectra of (a) 16μg CPT stock in 3ml of THF and 
(b) 16 μg dialyzed CPT (after removing releasing medium and dissolving in 3 ml of 
THF). 
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Table 2. Percentage of diffused CPT from the membrane to the release medium. 
 
Determination of optimum drug loading efficiency of PDAFBT was expressed in the 
following Figure 4.15 and Table 3.  In the first step, CPT solutions with respect to 
the same amount of loaded CPT in to the PDAFBT nanoparticles were prepared and 
the intensities of their absorbance were measured to plot a calibration curve. At the 
second step, the absorbance intensity of the free CPTsin the dialysate which are 
diffused out from the dialysis tube filled with CPT-loaded nanoparticles dispersion 
was measured. To obtain accurate result, the dialysate was evaporated to dryness and 
the remaining residue was dissolved in THF and the measurement was carried out in 
THF. It was observed that for the drug to polymer ratio of 1:35, respectively, 92% of 
the drug was encapsulated by the PDAFBT nanoparticles while for 1:25 (drug to 
polymer) ratio, 75% of the drug being encapsulated. 
 
Figure 4.15. UV-Vis absorption spectra of (a) 0.011 mg and 0.016 mg CPT stocks in 
THF as references (with respect to amount of CPT at 1:35 and 1:25 drug to polymer 
ratios). (b) dialyzed CPT which is loaded in PDAFBT at 1:35 and 1.25 drug to 
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polymer ratios.(After the removal of the releasing medium and dissolving in 3 ml of 
THF). 
 
 
Table 3. Percentage of loaded CPT by the PDAFBT nanoparticles for the CPT to 
PDAFBT, 1:35 and 1:25  : CPT ratios, respectively. 
Drug loading ability of nanoparticles was expressed in terms of ensapsulation 
efficiency (EE) defining the ratio of the amount of encapsulated drug to the total 
drug, and loading efficiency (LE) gives the ratio of amount of encapsulated drug to 
the total drug and nanoparticles as percentage shown in the following equations. 
 
 
Based on these equations, drug encapsulation efficiencies (EE) of PDAFBT 
nanoparticles are calculated to be as 92% and75% for the 1:35 and 1:25, 
respectively,for drug to polymer ratio. Drug loading efficiency of PDAFBT (LE) 
nanoparticles is calculated as 2.45% and 2.88% for the 1:35 and 1:25 respectively, 
for drug to polymer ratio. It can be concluded that the average drug loading 
efficiency of PDAFBT nanoparticles is 2.67±0.3 %. In order to achive maximal 
therapeutic effect drug loading efficiency has an significant role. In the literature 
there are various studies investigating the factors which affect drug loading 
efficiency. In the case of polymer nanoparticles polymer concentration, polymer 
solubility, interactions between polymer and drug, preparation methods are important 
parameters for loading efficiency and generally polymeric nanoparticles. For intance 
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it was reported, poly(lactic glycolic acid) nanoparticles which have high drug loading 
efficiency have high loading of CPT with 25%.  
4.2.4. Characterization of Drug Loaded PDAFBT Nanoparticles  
The number average size distributionof CPT loaded PDAFBT nanoparticles were 
measured as 20.3 and 24.4 for 1:35 and 1:25, respectively for drug to polymer ratios 
indicating that loading of polymers with drug does not cause significant size change 
in the nanoparticles. 
 
Figure 4.16. Number averagesize distribution by histogram from DLS measurements 
of CPT loaded PDAFBT nanoparticles for (a) 1:35 and (b) 1:25 drug to polymer 
ratios. 
Optical characterizations of drug loaded nanoparticles was obtained by UV-Vis 
absorption and fluorescence spectroscopies. CPT loaded PDAFBT nanoparticles 
have the same absorption maxima with the blank nanoparticles as shown in the 
Figure 4.15(a). In order to analyze their encapsulation efficiency by optically, 
absorption spectra of 1:35, 1:25 and additionally 1:10 drug to polymer ratios of 
PDAFBT nanoparticles solution were measured and observed that increasing amount 
of CPT results occurrence of a shoulder at 365 nm in the spectra due to CPT and 
those peak can be detected strongly for the highest CPT ratio (1:10) which shows 
non-encapsulated CPT. In the fluorescence spectrum emission band of CPT was seen 
at 440 nm when it is excited at 365 nm. As the polymer ratio increases, a shoulder at 
around 570 nm begins to appear which belongs to PDAFBT. The reason to observe 
emission intensity of CPT much more higher than PDAFBT nanoparticles could be 
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due to a minimum interaction of loaded CPT with the local environment caused by 
the protection of CPTs from the solvent molecules due to the surrounded polymer 
shell and that can lead to a high fluorescence intensity at the 365 nm excitation 
wavelength.  
 
 
Figure 4.17. (a) UV-Vis absorption (b) normalized fluorescence spectra of CPT 
loaded PDAFBT nanoparticles in water at different ratios.( ex= 366 nm). 
The images of blank and drug loaded nanoparticles under day light and UV light in 
the Figure 4.18 also suggest the high fluorescence intensity of CPT in drug loaded 
nanoparticles under UV light. Fluorescence emission is much more sensitive to the 
local environment than the UV-Vis absorption, thus nearly only absorption band of 
PDAFBT nanoparticles on the outer shell was detected in the UV-Vis spectrum 
while emission band of the protected CPT was observed much intensely in the 
fluorescence spectrum. 
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Figure 4.18. Photographic images of blank and CPT loaded PDAFBT nanoparticles 
under (a) day and (b) UV light. 
Morphological characterization of CPT loaded PDAFBT nanoparticles was done by 
TEM and the images are shown in the Figure 4.19 which reveal a correlation in sizes 
of nanoparticles measured by DLS and TEM.   
 
 
Figure 4.19. TEM image of CPT loaded PDAFBT nanoparticles.(CPT:PDAFBT is 
1:25) 
 
4.2.5. Determination Drug Release Profile of CPT Loaded PDAFBT 
Nanoparticles 
Drug release profile evaluates ability of nanoparticles to release drug over specific 
time period which is significant for therapeutic efficiency of drug carriers. Drug 
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release ability of PDAFBT nanoparticles was analyzed with the technique of dialysis 
membrane diffusion by supplying simple biological conditions (incubation at 37oC 
and 60 RPM) to force the diffusion of drug molecules from the polymer capsules. To 
study drug release profile, solution of CPT loaded PDAFBT nanoparticles at the 1:35 
drug to polymer ratio was placed in to the cellulose membrane and excess amount of 
phosphate buffer saline (PBS) with a few percent of Tween 20 was used as drug 
release medium. PBS buffer was used as release medium to mimic preliminarily 
conditions of human body because it provides desired isotonic environment and its 
osmolarility and ion concentrations resemble to the human body and tween 20 
enhances the solubility of released CPT in PBS buffer. To determine the amount of 
released drug, aliquots at specific volume were withdrawn from the release medium 
at different time intervals during the 50 hours-time period The concentration of the 
camptothecin in the release medium was measured by using UV-Vis absorption 
spectroscopy (λex=366 nm). 5 samples at known concentrationsin THF were used to 
obtain calibration curves to determine the concentration of unknown samples which 
is given in the Figure 4.20. 
(a)                                               (b) 
 
Figure 4.20. (a) UV-Vis absorption spectra of reference CPT stocks while increasing 
its amount ( ex = 366 nm). (b) Fit curve which represent the absorption curves of 
CPT stock. 
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Table  4. Percentage of loaded CPT by the PDAFBT nanoparticles for the CPT to 
PDAFBT, 1:35 and 1:25  : CPT ratios, respectively. 
UV-Vis absorption spectra of the withdrawn aliquots from the media were given in 
the Figure 4.21. The spectra was not clear and smooth like the spectra of reference 
CPT stocks due to effect of PBS and Tween 20 however it can be observed the 
intensity of peaks at 366 nm increases from 0 to 48 h time period.   
 
Figure 4.21. UV-Vis absorption spectra of samples withdrawn from the release 
medium at given time intervals. 
.  
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Table 5. UV-Vis absorbance, concentration values and percentage of released CPT 
at 48h time period. 
Concentration values of withdrawn samples from release medium in Table 4 were 
calculated by using linear fit curve of reference CPT stocks then concentration of 
released CPT in 100 ml of medium was obtained during 48h time period. In the drug 
release profile shown in the Figure 4.22, it was observed that after 20 hours 63% of 
total CPT was released and 95% of drug was diffused from the nanoparticles at 48. 
hours which shows there is no sudden, and burst release of CPT by polymer matrix 
degradation. The main mechanism of release of CPT from the PDAFBT 
nanoparticles has to be diffusion. Polymer matrix allows to leak of uniformly 
distributed drug molecules in the sphere. This is a preliminarily demonstration of 
drug release profile of PDAFBT, in order to improve the study, experiment will be 
repeated two more times and statistical outcome (with error bars) has to be obtained. 
However, this preliminary study is promising and suggests that release of CPT is not 
a sudden process and the result will be strengthen with two other measurements and 
detection over long time period. 
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Figure 4.22. Percentage release of CPT from PDAFBT nanoparticles during 48h. 
 
4.3. Biological Applications of Blank and Drug Loaded PDAFBT Nanoparticles  
This part consists of three major studies to investigate the efficiency of PDAFBT 
nanoparticles as drug carriers, imaging probes and understand the interactions of 
those nanoparticles with biological environments. In the first part,the stability of 
PDAFBT nanoparticles was analyzed at different biological media. In the second 
part,in vitrocytotoxicity assessment of blank and drug loaded nanoparticles was 
conducted; third part deals with exploring the ability of those nanoparticles as 
fluorescent probein vitro and in vivo assays. 
4.3.1 Determination of the Stability of Blank and Drug Loaded Nanoparticles in 
the Biological Media 
For the biological applications, interaction between material and biological system 
has to be understood and the level of biocompability should be determined especially 
to minimize the cytotoxicity of nanomaterial because when biomaterials are contact 
with cellsthey are encountered with an immunogenic response and recognized as a 
foreigner body. Herein, the interaction of PDAFBT nanoparticles with the human 
serum and bovine serum albumine (BSA) media was analyzed and the stability 
profile in those media was obtained. Firstly,stability of blank nanoparticles in water 
was analyzed by measuring their sizes with DLS during one week time period and 
observed that there is no significant change in the number average size distributions 
of blank nanoparticles over seven days. The results are given in the Figure 4.23.(a).  
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Secondly, those non-loaded nanoparticles were incubated in the BSA and human 
serum media by providing simple biological conditions (at 37oC, 60 RPM) then 
subsequently, the samples were taken at 0, 30 and 120 min. time intervals. As shown 
in the Figure 4.21 (b), a sudden increase in the size was observed for both samples 
incubated in BSA and human blood serum media due to adsorption of the proteins on 
the surface of nanoparticles via either protein layer formation or aggregation on the 
surface of nanoparticles. Hydrophobic interaction plays a major roles for the 
adsorption of the proteins on the surfaces of nanoparticles. Fluorene backbone in the 
PDAFBT nanoparticles provides desired hydrophobic surface for proteins in the 
media. Moreover, ion-dipole interaction between the local positive charges on 
proteins and lone pairs on the dimethylamine groups of nanoparticles has to be 
considered protein-polymer interaction. 
 
Figure 4.23. (a) Number avarage size change of blank PDAFBT nanoparticles in (b) 
Z-Avarage value (nm) of blank PDAFBT nanoparticles in human serum and BSA 
media masured by DLS. 
. 
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Figure 4.24. Schematic representation of interaction PDAFBT with proteins. 
The percentage amount of absorbed proteins in human serum was detected by using 
Bradford assay, which is a quantitative protein determination method by using 
coomassie brilliantblue G 250 dye. Under acidic conditions this dye exists in doubly 
protonated red cationic form but when it binds to a protein it forms a stable 
unprotonated blue form (Amax= 595 nm). Thus, the intensity of the blue protein-dye 
complexwas detected by using spectrometer at the 595 nm excitation. To detect the 
percentage adsorption of human serum proteins on the nanoparticles, the 
concentration of stock solution of human serum was accepted as 1X, several 
dilutions of this human serum stock was made and their absorbance maximum values 
were taken as reference. The calculated result indicates that only nearly 2.2% of 
proteins human serum adsorbed on the PDAFBT nanoparticles triggers the 
precipitation of nanoparticle solution dispersion. 
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Figure 4.25. Calculation of adsorbed proteins on surface of PDAFBT NPs in human 
serum through (a) calibration curve of stock solutions of human serum with respect 
to (b) absorbance values. 
Stability of CPT loaded PDFAFBT nanoparticles was investigated in water and cell 
culture medium (DMEM) during one week time period by DLS. It was observed that 
there is not significant size change of drug loaded nanoparticles in water over days in 
their storage conditions (5oC, 0 RPM). This also suggest that drug loaded 
nanoparticles preserve their shape and size unless encountering any destruction of 
polymer matrix which carries the drug. Before conducting the cell culture 
experiments of nanoparticles for different cell lines, stability of drug loaded 
nanoparticles in cell culture medium was determined and it was shown that the size 
of nanoparticles were nearly duplicated in DMEM given in the Figure 4.26 (b). 
DMEM supports the basal medium for growth of mammalian cells. Glucose and 
glycine in the content of DMEM can surround mildly the surface of nanoparticles 
and cause increase in size. Because the size of glycine and glucose are much lower 
than proteins, an acceptable size increase was observed rather than precipitation. 
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Figure 4.26. Calculation of adsorbed proteins on surface of PDAFBT NPs in human 
serum through (a) calibration curve of stock solutions of human serum with respect 
to (b) absorbance values. 
Stability experiments including interactions of drug loaded and blank PDAFBT 
nanoparticles with several media basically show that nanoparticles are almost stable 
in their non-treated, storage conditions, but in the case of protein environment, 
adsorption of proteins on the surface of nanoparticles is at the high level which leads 
decrease in their compatibility in the biological environments.  
 
4.3.2. Determination of In-vitro Cyctoxicity of Blank and CPT Loaded PDAFBT 
Nanoparticles 
Dose dependent in vitro cytotoxicity tests of the blank, camptothecin (CPT) loaded 
PDAFBT and free CPT against human breast carcinoma MDA-MB-231, MDA-MB-
157 and MCF 7 cells with different molecular subtypes and drug sensitivities 
performed using MTT assay. The reason of choosing three different cell lines was to 
compare their cytotoxic responses to the same model anticancer drug, using a well 
known anticancer drug, i.e. CPT, in the presense or absence of drug carriers. In order 
to analyze the sensitivity of cells to CPT, its chemical interaction with the cellular 
compartments has to be understood. CPT binds non-covalently to toposiomerase I, a 
nuclear enzyme which adjusts the topological state of DNA upon replication, -DNA 
complex and traps this complex. However,it was suggested that this complex can 
repair itself when degradation occurs through proteasomal pathway and the cells that 
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can achieve this repair mechanism indicates resistance to CPT.100 Another important 
suggestion for the resistance to CPT is alteration of the topoisomerase I with 
mutation or lower expression.101 The sensitivity of cells to chemicals was expressed 
with IC50 value which defines the inhibitory concentration of the drug to inhibit the 
biological process by half. The IC50 values obtained from literature shows that, CPT 
is extremely potent to the MDA-MB-157 cell line with IC50 value of 7 nm, while 
MCF-7 and MDA-MB-231 shows more resistance to CPT with the IC50 value of 
218nm and 250 nm.102-103 The effect of free and carried by polymer CPT on these cell 
lines were tested through the tetradiazole dye based cytotoxicty assays by 
considering their sensitivies to CPT. 
Before the analysis of the toxic effect of CPT loaded nanoparticles on the cancer 
cells, concentration based cytotoxicity of blank nanoparticles was assessed ranging 
from 0.312 μM to 40μM of PDAFBT concentration for the concerned cell lines and 
plotted as in the Figure 4.27. It was observed that while blank nanoparticles do not 
exhibit significant toxicity to MDA-MB-231 and MDA-MB-157 cells up to 40 μM, a 
linear decrease at the viability of MCF-7 cells was detected at higher concentrations 
than 2.5 μM and nearly 40% of the cells were dead at 40 μM PDAFBT nanoparticle 
solution. Instrinsic cell death mechanism of nanoparticles is not clear however this 
result suggests that different cell types develop different cytotoxicresponse to 
nanoparticles as foreign materials and in order to detect efficiency of drug carrier 
nanoparticles on cancer cells, blank nanoparticles can be used as negative control. 
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Figure 4.27. Percent cell viability results of PDAFBT nanoparticles on the MCF-7, 
MDA-MB-231 and MDA-MB-157 cell lines. 
 
Figure 4.28. Experimental set-up for MTT calorimetric assay in 96 well plates of 
CPT loaded PDAFBT nanoparticles with positive control of CPT, negative control of 
DMSO and blank PDAFBT nanoparticles. (Each treatment has three replicates in the 
set-up.) 
As mentioned before percent viability of cells was detected by tetraazolium dye 
toxicologic assay, named as MTT, which is chemically based on the reduction of 
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MTT dye to a blue formazan product by mitacondrial dehydrogenases enzyme of live 
cells.104 The MTT protocol was applied according to instructions of Invitrogen. The 
intensity of purple formazan product shows the viability of cells that were plated into 
96 well plates (2000 cells) after 24 hours cells were treated with free CPT in DMSO, 
blank PDFABT nanoparticles, CPT loaded Nanoparticles and DMSO. After 48h 
treatment, live cells were quantified by measuring the absorbance intensity (optical 
density) of blue formazan product at 570 nm. In the experimental set-up which is 
shown in the Figure 4.28, free CPT was used as positive control, DMSO and blank 
nanoparticles were as negative control to CPT loaded nanoparticles. The cell 
viability results in percentage of each cell line were demonstrated in the Figure 4.29. 
Each cell line exhibits generally a similar trend to exposures by decreasing the 
number of viable cell but the percentage of cell deaths changes with respect to the 
sensitivity of cell line to PDAFBT nanoparticles and CPT. When the MDA-231 cell 
line was analyzed, it was seen that while the toxic effect of free CPT on the cells is 
nearly 35%, toxic effect of blank nanoparticles decreases by half at the same CPT 
loaded PDAFBT concentrations. In the case of CPT loaded nanoparticles, nearly 
70% of cell deathwas observed at 2μM CPT level which is much higher than the sum 
ofseperatetoxic effects of blank nanoparticles and CPT. This result preliminarily 
suggests the idea of cell death through synergic effect between nanoparticle and 
drug, rather than additive effect due to sum of them. IC50 values of CPT and CPT 
loaded PDAFBT NPs were calculated and found as 1.97μM and 1.05μM. This means 
internalization of the same amount of CPT was more efficient by transporting in 
PDAFBT nanoparticles rather than in free form. MDA-MB-157 cell line also 
confirms the toxicity results of MDA-MB-231 cells. Toxicity of PDAFBT Nps and 
CPT are nearly in the same level with roundly 25% at high concentrations, but CPT 
loaded nanoparticles kill the nearly 70% of the cells at 2μM CPT concentration. IC50 
value of CPTloaded nanoparticles was only 1.35μM while IC50 value of free CPT 
was 4.5 μM  which shows the high efficiency of delivery of CPT in nanoparticles. 
However , in MCF7 nanotparticle CPT combination exhibited a relatively slower 
action on cell compared to other cell lines, and at 2 μM the effect of campothecin 
was similar to that of nanoparticle CPT complex in one of the experiments but in the 
other there was a significant difference (Appendix A). Across all concentrations and 
in all cell lines, PDAFBT-CPT complex exhibited more effect against viability 
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compared to CPT or PDAFBT alone, suggesting that PDAFBT is a highly effective 
drug carrier. IC50 values were calculated based on untransformed drug 
concentrations (Table 5). One possibility is calculate IC50 induction after 
normalization to controls (i.e., dmso for campothecin and PDAFBT for PDAFBT-
CPT) and calculate a single IC50 showing the effect of nanoparticle (Table 5). 
However, at 2 μM, not all cell lines resulted in 50% reduction in cell viability thus it 
is difficult to estimate an exact IC50 for MDA157. Thus other methods of drug 
effectivity, such as Amax and area under curve (AUC) can be explored in the future 
studies105. These initial findings indicate that MDA157 exhibits the most striking 
effect of the nanoparticle followed by MDA231 and MCF7 cell lines  
 
Figure 4.29. Percent cell viability results of (a) MDA-MB-231 (b) MDA-MB-157 
and (c) MCF-7 cell lines after 4h MTT treatment. 
 
66 
 
 
Table 6. IC50 values of free CPT and CPT loaded PDAFBT nanoparticles for MDA-
MB-231, MDA-MB-157 and MCF-7 cell lines. 
A comparison between the sensitivity of the cell lines to an anti cancer drug and 
morphology of cells can be make by checking the molecular and cellular phenotype 
of the cells. MDA-MB-231, MDA-MB-157 and MCF-7 cells have differences in 
their estrogen and progesterone receptor status as well as migratory characteristics 
that can contribute to the differences observed in NP toxicity and effectivitys106-108 
Therefore future studies are needed to construct a releationship between the 
morhologies of the concerning cell lines and their sensitivies to nanoparticles 
carrying CPT. 
Cell viability experiments were repeated two-three times with different 
concentrations and that results for MDA-MB-231 and MDA-MB-157cell lines are in 
high conformity by exhibiting efficient internalization of CPT through the PDAFBT 
nanoparticles. (Appendix A) Furthermore, each cell line shows similar response to 
the same chemicals with changing in viability. The results of sensitivity to CPT of 
concerning cell lines in these experiments are not same with the literature values 
reporting the CPT sensitivity of resulting cell lines but sensitivity this maybe due to 
differences in cell passage numbers and from different batches, phases in the cell 
cycle also another critical parameter defining the drug sensitivity.109 It can be 
preliminarily deduced than from the cytotocity results PDAFBT nanoparticles can be 
used for diasnogtics approach.  
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4.3.3. In Vitro and In Vivo Screening of blank PDAFBT and PPFBT 
Nanoparticles  
4.3.3.1.Identification of PDAFBT Treated Cells by BrdU Labeling  
5-Bromo-2-deoxyurine (BrdU) is a synthetic thymine analog incorporated to DNA 
during the cell division and to trace the proliferation of cells. BrdU can quantify the 
number of newborn cells in the time period of its treatment and labeling BrdU 
fluorescently provides to screen the cells by fluorescence microscope.110 DNA 
incorporated BrdU can be detected by using specific monoclonal primary antibodies 
and fluorescent dye conjugated secondary antibodies which can bind to these primary 
antibodies to provide detection of cells by fluorescent screening. 
 
Figure 4.30. Identification of PDAFBTtreated MCF-7 cells through BrdU labeling. 
(a) Stained nuclei with DAPI (b) Detection of BrdU incorporation using BrdU 
Mouse mAB#52925 and Anti Mouse IgG (H+L) #4409, F(ab’)2 (Alexa Fluor 555) 
(c) Internalizaed PDAFBT NPs (30μM)  into the cells. (d) Merged images of (a), (b) 
and (c). (40X magnification with blue, yellow, red filters.) 
Herein, PDAFBT treated MCF-7 cells were screened by fluorescently labeling BrdU 
and a round estimation was made about the effect of nanoparticles on cell 
proliferation. In this experiment, BrdU mouse mAB was used as primary antibody to 
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detect BrdU reagentbound to single stranded DNA and Alexa fluor 555 conjugated 
anti Anti- Mouse IgG was used as secondary antibody to screen the cells having red 
emission according to manufacturer’s instructions111 (Cell Signaling). It is important 
to adjust the time of treatment of BrdU because it is potentially toxic for the cells due 
to bromide group in its structure. After 48h incubation of the cells with PDAFBT 
nanoparticles, BrdU reagent was given for 2h. The exposure of PDAFBT NPs and 
BrdU reagent to MCF-7 cells were shown in the Figure 4.30. In order to to 
distinguish the cellular boundaries, nuclei were stained with DAPI. Stained nuclei 
with DAPI (blue) and BrdU (red) (Figure 4.30a-b) can be select effectively. 
Fluorescent images in the Figure 4.30 (c-d) shows that PDAFBT nanoparticles were 
internalized efficiently by the cells and they accumulate mostly in the perinuclear 
reagion of the cells. The cells which make red fluorescence emission are newly 
proliferated cells after BrdU incorporation. Cell proliferation efficiency after 
exposure of PDAFBT nanoparticles were not evaluated quantitatively but from the 
images it can be seen that cell proliferation continues after PDAFBT 
treatment.Additionally it was observed that, while fluorescent intensity of DAPI 
decreased enormously after one month storage, there is not any significant change in 
the brightness of PDAFBT nanoparticles which demonstrates the photostability of 
PDAFBT nanoparticles for long term period (Figure 4.31) 
 
Figure 4.31. PDAFBT NPs internalized MCF-7 cells (a) right after DAPI 
staining.(b) after one month storage. 
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4.3.3.2 In Vivo Screening of PDAFBT nanoparticles in Zebrafish Embryos as 
Model Organism 
Embryonic zebrafish is used as an ideal model system for in vivo imaging due their 
transparency and ability to develop rapid and stereotyped embryonic central nervous 
system.112 There are studies reporting exposuring fluorescent organic molecules and 
fluorescent silica nanoparticleson zebrafish embryos but there is no study consisting 
whole body imaging of embryonic zebra fish with fluorescent conjugated polymer 
nanoparticles. 113-114 
Here a preliminarily study, the accumulating of PDAFBT nanoparticles on zebrafish 
embryos was visualized by fluorescent microscope. Zebrafish embryos at 48h dpf  
were treated with CPT, DMSO,blank and CPT loaded PDAFBT nanoparticles at 
different concentrations followed by washing and fixing with paraformaldehyde. 
After 24 hours exposure, it was observed that there is not significant effect of on the 
development of  zebra fish embryos treated with DMSO and blank nanoparticles 
while negative effect onsurvial of embryos was encountered treated with free CPT 
and CPT loaded nanoparticles at 2 μM drug concentration. Zebrafish embryos treated 
with 0.5μM free CPT and blank nanoparticles and drug loaded nanoparticles revealed 
that nanoparticles accumulate on the skin of the embryos, particularly 
ventrally.(Figure 4.32). The intensity of the fluoresence of the NPs allow 
visualization incontrast to the autofluorescence from the embyros itself. Future 
studies will involve microinjection of a given amount of blank nanoparticle and drug 
loaded nanoparticle combination to visualize the effect internally. Also, zebrafish 
starts feding at 5 dpf, thus nanoparticles might be orally available to the embryos 
thus effects can be further analyzed. 
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Figure 4.32. Fluorescence microsope images of embryonic zebra fish (48h pf) 
exposured to (a) DMSO (% 1), (b) CPT (0.5 μM) (c) PDAFBT NPs (2μM) (d) CPT 
loaded PDAFBT NPs (0.5 μM). (λem= 480-550 nm), 40X) 
 
4.3.3.3.In Vivo Screening and Toxicity Assesment of PPFBT nanoparticles in C. 
Elegans as a Model Organism 
In this part, in vivo visualization and primary toxicity investigation of previously 
synthesized Poly[9,9-bis{propenyl}fluorenyl-2,7-diyl))-co-(1,4-benzo{2,1,3}-
thiodiazole)]  (PPFBT) nanoparticles 115  were appliedby using C. Elegans  as model 
organism due to its transparency and easy handling. In vitro cytotoxicty of PPFBT 
nanoparticles was assessed previously and IC50 value of  free CPT and CPT loaded 
PPBT nanoparticles were found as 0.9 μM and 0.1μM respectively, indicating the 
high efficiency of internalization of CPT through these nanoparticles.116 Herein, as a 
next step of its biomedical applications, a primary study to determine in vivo imaging 
ability and toxicity of PPFBT nanoparticles was conducted. Penetration of PPFBT 
nanoparticles to adult C. Elegans (L4 phase) was determined after 30 min exposure 
time and fixation.  
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Figure 4.33. (a) Fluorescence microscope images of (a) non treated, PPFBT NPs 
(0.01 mM) stained C. Elgans (L4) at (b) 20X (c) 40X (d-f) 20X magnifications 
(λem=  480-550 nm)  (g) Shematic drawing of anatomy of an adult hermafrodite.117 
 
Fluorescence images of PPFBT loaded nanoparticles in C. Elegans taken by 
fluorescence microscope with green filter was shown in the Figure 4.33. Images 
primarily suggest that nanoparticles are efficiently uptaken by worms and 
accumulate mainly in on the gonad and phyranx of the animal.  
Toxic effect of PPFBT nanoparticles on C. Elegans was examined primarily by 
counting of progeny after treatment with 0.01mM nanoparticles for 5 days time 
period in parallel with untreated control groups. It was observed that PPFBT treated 
worms at given concentration continue to proliferate like untreated worms with an 
acceptable decrease as shown in the Figure 3.34. This very primary result is 
promising to enhance the in vivo studies of PPFBT nanoparticles by optimizing the 
time and dose dependent applications. 
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Figure 4.34. Number of progeny of nontreated and PPFBT treated C. Elegans in 5 
days time period. 
Cell viability assasy through MTT and in vitro and in vivo imaging capability results 
show that these nanoparticles can be deeply analyzed for theranostic applications 
which is based on imaging guided drug delivery phenomena. 
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CHAPTER 5 
5. CONCLUSION 
 
In this thesis, imaging guided drug carrier system based on conjugated polymers 
nanoparticleswas developed and their efficiency to deliver water insoluble anticancer 
therapeutic camptothecin into cells was investigated.  
Fluorene based conjugated polymer, PDAFBT, was synthesized through Suzuki 
Coupling and characterized by H1-NMR, C13-NMR, ESI-MS, MALDI, FTIR, UV-
Vis absorption and Fluorescence spectroscopies. PDAFBT nanoparticles were 
synthesized through reprecipitation technique and characterized by DLS, TEM, SEM 
methods and nearly 25nm number avarage size distribution with PDI lower than 0.2 
was detected for the uniform nanoparticles In order to obtain drug carried 
nanoparticles, anticancer drug camptothecin was entrapped into PDAFBT 
nanoparticles through hydrophobic and 𝝅-𝝅 interactions. Drug encapsulation 
efficiency (EE) was found as 92% and 75% for the 1:35 and 1:25 polymer to drug 
ratios. Through this investigation, drug loading efficiency of PDAFBT nanoparticls 
(LE) was determined as 2.67±0.3 %. Preliminary drug relase profile which will be 
strengthen statistically, of PDAFBT nanoparticleswas analyzed and showed that 
nearly 100 % of loaded CPT was released in 48h time period and release of CPT is 
not a sudden process. In vitro dose dependent cytoxicity assay MTT on MDA-MB-
231, MDA-MB-157 and MCF-7 cells indicates that PDAFBT nanoparticles do not 
exhibit significant toxicity. IC50 values of free CPT and CPT loaded PDAFBT NPs 
were 4.50μM and 1.35μM for MDA-157 cell line and 1.97μM and 1.05μM for 
MDA-MB-231 cells which shows efficient internalization of CPT into MDA-MB-
157 and MDA-MB-213 cell line through these polymer capsules.Preliminarily in 
vivo imagings of PDAFBT and PPFBT nanoparticles on embryonic zebra fish and C. 
Elegans models suggest that efficient internalization of nanoparticles by tissues 
andin-vivo monitoring of PDAFBT nanoparticles is promising for time and dose 
dependent treatments as a future direction. 
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APPENDIX  A 
 
 
Figure A. 1. ESI-MS spectrum of PDAFBT. ([m/z]+1 = 1684) 
 
 
Figure A. 2. ESI-MS spectrum of PDAFBT.([m/z]+1 = 1805) 
 
 
Figure A. 3. ESI-MS spectrum of PDAFBT. ([m/z]+1 = 1739) 
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Figure A. 4. Size distrubution histogram of  PDAFBT nanoparticles for the detection 
of their stability in size. (0th day sample -1) 
 
Figure A. 5. Size distrubution histogram of  PDAFBT nanoparticles for the detection 
of their stability in size (0th day , sample-2) 
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Figure A. 6. Size distrubution histogram of  PDAFBT nanoparticles for the detection 
of their stability in size. (0th  day- sample-3) 
 
 
Figure A. 7. Size distrubution histogram of  PDAFBT nanoparticles for the detection 
of their stability in size. (3rd day, sample-1) 
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Figure A. 8. Size distrubution histogram of  PDAFBT nanoparticles for the detection 
of their stability in size. (3rd day- Sample-2) 
 
Figure A. 9. Size distrubution histogram of  PDAFBT nanoparticles for the detection 
of their stability in size. (3rd day, Sample-3) 
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Figure A. 10. Size distrubution histogram of  PDAFBT nanoparticles for the 
detection of their stability in size. (7th day, Sample-1) 
 
Figure A. 11. Size distrubution histogram of  PDAFBT nanoparticles for the 
detection of their stability in size. (7th day, Sample-2) 
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Figure A. 12. Size distrubution histogram of  PDAFBT nanoparticles for the 
detection of their stability in size. (7th day, Sample-3) 
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Figure A. 13. Cell Viability Assay of blank and non-loaded PDAFBT NPs on MDA-
MB-157. (Replicate-2) 
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Figure A. 14.  Cell Viability Assay of blank and non-loaded PDAFBT NPs on 
MDA-MB-231. (Replicate-2) 
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Figure A. 15. Cell Viability Assay of blank and non-loaded PDAFBT NPs on MCF-
7. (Replicate-2) 
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